



ISPOR 20th Annual
International Meeting

May 16-20, 2015
Philadelphia Marriott Downtown
Philadelphia, PA, USA



Research Poster Presentations – Session V

Wednesday, May 20, 2015

8:30AM-2:45PM

Poster Author Discussion Hour:

12:45PM-1:45PM

Research Poster Presentations – Session V includes the following topics

PHS – HEALTH SERVICES

Rows A-J

PND – NEUROLOGICAL DISORDERS **Rows J-N**

PSY – SYSTEMIC DISORDERS/CONDITIONS **Rows N-X**

A1 Location of the poster in the poster hall – please refer to last page for a floor plan

pgA10 Location of the abstract as published in *Value in Health* Volume 18, Issue 3

RESEARCH POSTER PRESENTATIONS - SESSION V

HEALTH CARE TREATMENT STUDIES

HEALTH SERVICES - Clinical Outcomes Studies

- PHS1 A1 pgA247 MEDICATION UTILIZATION IN INCIDENT ADVERSE DRUG REACTIONS OF CANCER CHEMOTHERAPY - A PHARMACIST PERSPECTIVE**
Guntupalli L, chalapathi institute of pharmaceutical sciences, guntur, AA, India
- PHS2 A2 pgA247 SENTINEL SITE ACTIVE SURVEILLANCE OF THE SAFETY OF FIRST-LINE ANTIRETROVIRAL MEDICINES IN NAMIBIA**
Mann M¹, Mengistu A², Gaeseb J³, Sagwa E⁴, Mazibuko G⁴, Garrison LP¹, Stergachis A¹,¹University of Washington, Seattle, WA, USA, ²Therapeutics Information and Pharmacovigilance Centre Namibia, Windhoek, Namibia, ³Ministry of Health and Social Services Namibia, Windhoek, Namibia, ⁴Management Sciences for Health, Windhoek, Namibia
- PHS3 A3 pgA248 CACHEXIA & DEBILITY IN HOSPITALIZED CHILDREN WITH COMPLEX CHRONIC CONDITIONS**
Van Doren BA¹, Roy D¹, Noone J², Blanchette CM², Arthur S²,¹University of North Carolina, Charlotte, Charlotte, NC, USA, ²University of North Carolina at Charlotte, Charlotte, NC, USA
- PHS4 A4 pgA248 PATIENT AND HOSPITAL-LEVEL FACTORS ASSOCIATED WITH INPATIENT MORTALITY OF STROKE PATIENTS**
Sharma M, Ferries EA, Yucel A, Johnson ML, Aparasu R, University of Houston, Houston, TX, USA
- PHS5 A5 pgA248 CONTEXTUAL ANALYSIS OF DETERMINANTS OF LATE DIAGNOSIS OF HEPATITIS C VIRUS INFECTION IN MEDICARE PATIENTS**
Chirikov VV¹, Shaya FT¹, Howell CD²,¹University of Maryland School of Pharmacy, Baltimore, MD, USA, ²Howard University College of Medicine, Washington, MD, USA
- PHS6 A6 pgA248 RISKS OF FRACTURES IN VITILIGO PATIENTS TREATED WITH PHOTOTHERAPY**
Li C¹, **Lo P**², Huang W², Wen Y³, Tsai Y², Tsai T⁴,¹National Taiwan University College of Medicine, Taipei, Taiwan, ²National Yang Ming University, Taipei, Taiwan, ³Chang Gung University, Taoyuan, Taiwan, ⁴National Taiwan University Hospital, Taipei, Taiwan
- PHS7 A7 pgA248 REMOTE MONITORING STRATEGIES FOR PATIENTS WITH STABLE HEART FAILURE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS**
Pandor A, Gomersall T, Stevens JW, Wong R, The University of Sheffield, Sheffield, UK
- PHS8 A8 pgA248 PERFORMANCE OF TWO WORLD HEALTH ORGANIZATION DENGUE CLASSIFICATIONS IN A PEDIATRIC COHORT FROM COLOMBIA**
Pinzón-Redondo H¹, Paternina-Caicedo A², **Alvis-Guzman N**², Diaz-Quijano F³, Zarate-Vergara A⁴, Barrios-Redondo K⁴, De la Hoz-Restrepo F⁵,¹Hospital Infantil Napoleón Franco Pareja, Cartagena., Colombia, ²Universidad de Cartagena, Centro de Investigación y Docencia, Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, ³Universidad de Sao Pablo. Departamento de Salud Pública, Sao Pablo, Brazil, ⁴Hospital Infantil Napoleón Franco Pareja, Cartagena, Colombia., Colombia, ⁵Instituto Nacional de Salud, BOGOTA D.C., Colombia
- PHS9 A9 pgA249 IS PHARMACEUTICAL CARE EFFECTIVE FOR IMPROVING BLOOD PRESSURE CONTROL AND MEDICATION ADHERENCE AMONG HYPERTENSIVE PATIENTS? A REVIEW**
Eziyi A, Adunlin G, Florida A & M University, Tallahassee, FL, USA
- PHS10 A10 pgA249 EFFECTS OF SOCIAL NETWORKS ON PATIENT ADHERENCE TO PRESCRIBED TREATMENT FOR SERIOUS MENTAL ILLNESS: A SYSTEMATIC REVIEW**
LyttleNquessan CJ, Campbell ES, Florida A&M University, Tallahassee, FL, USA
- PHS11 A11 pgA249 PREDICTORS OF ALLOPURINOL ADHERENCE IN PATIENTS WITH GOUT**
Singh Ja, UAB SCHOOL OF MEDICINE, Birmingham, AL, USA
- PHS12 A12 pgA249 COMPARISON OF THE IMPACT OF HUMAN VERSUS ANALOGUE INSULINS ON GLYCOSYLATED HEMOGLOBIN IN A POPULATION WITH DIABETES MELLITUS COLOMBIA**
Machado J, Medina D, Universidad Tecnológica de Pereira, Pereira, Colombia
- PHS13 A13 pgA249 MANAGEMENT OF TUBEROUS SCLEROSIS COMPLEX IN ENGLAND: INSIGHTS INTO REAL-WORLD CLINICAL PRACTICE**
Kingswood C¹, Dew R², **Gray E**³,¹(On behalf of the TSC clinic network) The Royal Sussex County Hospital, Brighton, UK, ²pH Associates Ltd, Marlow, UK, ³Novartis Pharmaceuticals UK Ltd, Frimley, UK
- PHS14 A14 pgA249 PREDICTORS OF CIGARETTE SMOKING IN THREE ASIAN COUNTRIES: CHINA INDIA AND TAIWAN**
Almogbel Y, Abughosh S, Essien EJ, Sangsiry SS, University of Houston, Houston, TX, USA
- PHS15 A15 pgA250 ASSESSMENT OF AWARENESS REGARDING HEPATITIS B AMONG WOMEN IN ABBOTTABAD, KPK PAKISTAN**
Azhar SA¹, Hassali AA², Sana SS¹, Faiza FI¹, Zainab ZB¹, Sundas SA¹, Mahrukh MA¹, Noman NH³, Fahad FS², Izhar IH¹,¹COMSATS Institute of Information Technology, Abbottabad, Pakistan, ²Universiti Sains Malaysia,

Penang, Malaysia, ³University of Balochistan, Quetta, Pakistan

- PHS16 A16 pgA250 PREVALENCE AND BURDEN OF ALPHA-1 ANTITRYPSIN DEFICIENCY AMONG HOSPITALIZED COPD PATIENTS IN THE US**
Blanchette CM¹, Noone J¹, Roy D², Van Doren BA¹, Zacherle E¹, Howden R¹,¹University of North Carolina at Charlotte, Charlotte, NC, USA, ²University of North Carolina, Charlotte, Charlotte, NC, USA
- PHS17 A17 pgA250 RACIAL DISPARITIES IN TOTAL ANKLE ARTHROPLASTY UTILIZATION AND OUTCOMES**
Singh Ja, Ramchandran R, UAB SCHOOL OF MEDICINE, Birmingham, AL, USA
- PHS18 A18 pgA250 PREVALENCE AND BURDEN OF ANKLE INJURIES IN NORTH CAROLINA EMERGENCY DEPARTMENTS**
Shah S, Blanchette CM, Noone J, Wikstrom EA, University of North Carolina at Charlotte, Charlotte, NC, USA
- PHS19 A19 pgA250 NATIONAL TRENDS AND CHARACTERISTICS OF PSYCHIATRIC ADMISSIONS IN US EMERGENCY DEPARTMENTS: 2006-2011**
Vohra R, Madhavan SS, Sambamoorthi U, West Virginia University, Morgantown, WV, USA
- PHS20 A20 pgA250 BURDEN OF DISEASE OF HEPATITIS C IN COLOMBIA**
Alvis-Guzman N¹, Romero M², De la Hoz-Restrepo F³,¹Universidad de Cartagena, Centro de Investigación y Docencia, Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, ²Fundación Salutia, Bogotá D.C., Colombia, ³INSTITUTO NACIONAL DE SALUD, Bogotá, Colombia
- PHS21 A21 pgA251 EXAMINING RISK FACTORS AND PREDICTING READMISSIONS IN COPD PATIENTS**
Sickler A, Wang QC, Chawla R, Nigam S, Independence Blue Cross, Philadelphia, PA, USA
- PHS22 B1 pgA251 TREATMENT FOR SUBSTANCE USE AND IMPLICATIONS FOR MORTALITY IN ELDERLY PROSTATE CANCER PATIENTS**
Chhatre S, Malkowicz SB, Metzger DS, Jayadevappa R, University of Pennsylvania, Philadelphia, PA, USA
- PHS23 B2 pgA251 RELATION BETWEEN HEALTH INSURANCE COVERAGE AND OUTCOMES AMONG WOMEN WITH BREAST CANCER IN FLORIDA**
Tawk RH¹, Ali A², Adunlin G², Xiao H²,¹Florida A&M University, Tallahassee, FL, USA, ²Florida A & M University, Tallahassee, FL, USA

HEALTH SERVICES - Cost Studies

- PHS24 B3 pgA251 PERIPHERAL ARTERIAL DISEASE MANAGEMENT PROGRAM: SCREENING-RISK FACTOR MANAGEMENT PROGRAM AND FINANCIAL RETURN ON INVESTMENT**
Luque A¹, Junqueira Junior SM², Cabra HA³, Andrade PC², Oliveira FM¹,¹Johnson & Johnson Medical Brazil, São Paulo, Brazil, ²Johnson & Johnson Medical Brazil, Sao Paulo, Brazil, ³Johnson & Johnson Medical, Mexico, D.F., Mexico
- PHS25 B4 pgA251 ECONOMIC BURDEN OF ADVERSE EVENTS ASSOCIATED WITH FIRST LINE METASTATIC RENAL CELL CARCINOMA (MRCC) TREATMENT IN PUBLIC AND PRIVATE BRAZILIAN PERSPECTIVE**
Ferreira CN, Santana CF, Rufino CS, Pfizer Brasil, São Paulo, Brazil
- PHS26 B5 pgA252 IMPACT OF NON-MEDICAL SWITCHING ON HEALTHCARE COSTS: A CLAIMS DATABASE ANALYSIS**
Liu Y¹, Skup M², Lin J³, Chao J²,¹University of Missouri-Kansas City, Kansas City, MO, USA, ²AbbVie Inc., North Chicago, IL, USA, ³Novosys Health, Green Brook, NJ, USA
- PHS27 B6 pgA252 INCREASED HEALTHCARE UTILIZATION ASSOCIATED WITH OBESITY**
Hoshen MB, Balicer R, Clalit Health Services, Tel Aviv, Israel
- PHS28 B7 pgA252 COST OF IMPLEMENTING A PEDIATRIC NEUROCRITICAL CARE CENTER**
Buchanan P¹, Howard S¹, Zhang Z¹, Buelt C¹, Pearson L¹, Huetsch M¹, Gill J², Pineda J²,¹Saint Louis University, Saint Louis, MO, USA, ²Washington University, Saint Louis, MO, USA
- PHS29 B8 pgA252 DIFFERENCES IN THE TOTAL HEALTHCARE COSTS DURING THE YEAR OF DIAGNOSIS BETWEEN APPALACHIAN AND A NATIONAL COHORT OF ELDERLY WOMEN WITH BREAST CANCER: AN APPLICATION OF DECOMPOSITION TECHNIQUE**
Vyas A¹, Madhavan SS², Sambamoorthi U², Pan X³, Regier M², Hazard H²,¹Rutgers University, Piscataway, NJ, USA, ²West Virginia University, Morgantown, WV, USA, ³Evidera LLC, Lexington, MA, USA
- PHS30 B9 pgA252 ASSESSING THE FULL BURDEN OF CARE FOR AGITATION IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR I DISORDER**
Margolis MK¹, Bapat B², Blume S¹, Cicero S³, Gandhi SK³,¹Evidera, Bethesda, MD, USA, ²Evidera, Lexington, MA, USA, ³TEVA Pharmaceuticals, Frazer, PA, USA
- PHS31 B10 pgA252 COMMON REASONS FOR AND ASSOCIATED COSTS OF PEDIATRIC INPATIENT ADMISSIONS IN THE UNITED STATES**
Meyers J, Candrilli S, RTI Health Solutions, Research Triangle Park, NC, USA
- PHS33 B11 pgA253 DIRECT MEDICAL COST OF COMPLICATIONS IN PATIENTS WITH NON VALVULAR ATRIAL FIBRILLATION NVAF AT A PRIVATE HOSPITAL IN VENEZUELA**
Fernandez Y¹, Chiquinquirá K², **Garrido Lecca S**³,¹Universidad Central de Venezuela Facultad de Medicina Escuela de Salud Pública, Caracas, Venezuela, ²Unesar Clinica Santa Sofia, Caracas, Venezuela, ³Bristol-Myers

Squibb, Lima, Peru

- PHS34 B12** *pgA253* **DIRECT COSTS OF HEALTHCARE OF MULTIPLE SCLEROSIS, THE CASE OF A HEALTH MAINTENANCE ORGANIZATION IN COLOMBIA**
Muñoz-Galindo IM¹, Moreno JA¹, Guarín NE¹, Díaz JA², Arevalo HO¹,¹Salud Total EPS, Bogotá D.C., Colombia, ²Universidad Nacional de Colombia, Bogotá D.C., Colombia
- PHS35 B13** *pgA253* **INCREMENTAL BURDEN OF GROUP 3 PULMONARY HYPERTENSION PATIENTS TO U.S. PAYER**
Heresi GA¹, Joish VN², Platt D³, Abad M⁴, Kamalakar R³, Teal S⁴, Satler C³,¹Department of Pulmonary and Critical Care Medicine, Cleveland, OH, USA, ²Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA, ³BAYER HEALTHCARE PHARMACEUTICALS, WHIPPANY, NJ, USA, ⁴Bayer Pharma AG, Berlin, Germany
- PHS36 B14** *pgA253* **HOSPITALIZATION COSTS DUE TO SEVERE ACUTE RESPIRATORY INFECTION (SARI) IN THREE CENTRAL AMERICAN COUNTRIES**
Alvis-Guzmán N¹, Marin-Correa C², Castañeda-Orjuela C², Sanchez-Ruiz C³, Carrasquilla-Sotomayor M⁴, Sanchez F⁵, Mena R⁶, Mejía H⁷,¹Universidad de Cartagena. Centro de Investigación y Docencia. Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, ²Instituto Nacional de Salud, BOGOTÁ D.C., Colombia, ³TEPHINET, Bogota D.C., Colombia, ⁴Universidad de Cartagena, Centro de Investigación y Docencia, Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, ⁵Universidad Autónoma de Nicaragua, Managua, Nicaragua, ⁶Hospital General San Juan de Dios, San Lucas Sacatepequez, Guatemala, ⁷Secretaría de Salud, Tegucigalpa, Honduras
- PHS37 B15** *pgA253* **RACIAL VARIATION IN THE CLINICAL AND ECONOMIC BURDEN OF SKELETAL-RELATED EVENTS AMONG ELDERLY MEN WITH STAGE IV METASTATIC PROSTATE CANCER**
Jayasekera J¹, Onukwugha E¹, Bikov K¹, Hussain A²,¹University of Maryland School of Pharmacy, Baltimore, MD, USA, ²University of Maryland School of Medicine, Baltimore, MD, USA
- PHS38 B16** *pgA253* **COST OF COLORECTAL CANCER IN VIETNAM**
Nguyen T, Phan T, Nguyen TT, University of Medicine and Pharmacy in HCMC, Ho Chi Minh City, Vietnam
- PHS39 B17** *pgA254* **DIRECT MEDICAL COSTS ASSOCIATED WITH CLINICAL AND HEALTH CHARACTERISTICS IN VISUALLY IMPAIRED INDIVIDUALS IN SINGAPORE**
Luo N¹, Wang X¹, Finkelstein EA², Lamoureux E³, Aung T⁴, Wong TY⁴, Ang M⁴,¹National University of Singapore, Singapore, Singapore, ²Duke-NUS Graduate Medical School, Singapore, Singapore, ³Duke, Singapore, Singapore, ⁴Singapore National Eye Center, Singapore, Singapore
- PHS40 B18** *pgA254* **ECONOMIC BURDEN OF VACCINE-PREVENTABLE DISEASES AMONG THE ELDERLY IN TAIWAN**
Lu W¹, Yang HK², Chen L³, Hsiao F¹,¹National Taiwan University, Taipei, Taiwan, ²Merck & Co., Inc., West Point, PA, USA, ³Taipei Veterans General Hospital, Taipei, Taiwan
- PHS41 B19** *pgA254* **DIRECT COSTS OF HEALTH CARE FOR BREAST CANCER, THE CASE OF A HEALTH MAINTENANCE ORGANIZATION IN COLOMBIA**
Moreno JA¹, Muñoz-Galindo IM¹, Guarín NE¹, Díaz JA², Arevalo HO¹,¹Salud Total EPS, Bogotá D.C., Colombia, ²Universidad Nacional de Colombia, Bogotá D.C., Colombia
- PHS42 B20** *pgA254* **CLINICAL AND ECONOMIC ANALYSIS OF SIMPLE CONTACT DERMATITIS DUE TO URINARY INCONTINENCE AND PRESSURE ULCERS OF IMMOBILIZED PATIENTS WITH URINARY INCONTINENCE**
Vorobiev A, Vorobiev P, Krasnova L, Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia
- PHS43 B21** *pgA254* **ECONOMIC BURDEN OF COLORECTAL CANCER IN VIETNAM: FROM HEALTHCARE PAYERS' PERSPECTIVE**
Phan T, Hoang B, Nguyen TT, University of Medicine and Pharmacy in HCMC, Ho Chi Minh City, Vietnam
- PHS44 C1** *pgA254* **MEDICAL CARE COSTS OF CHIKUNGUNYA VIRUS INFECTION IN A PEDIATRIC POPULATION IN COLOMBIA**
Castañeda-Orjuela C¹, Díaz-Jiménez D¹, Rodríguez-Castillo L¹, Paternina-Caicedo A², Pinzón-Redondo H³, Alvis-Guzmán N², De la Hoz-Restrepo F¹,¹Instituto Nacional de Salud, BOGOTÁ D.C., Colombia, ²Universidad de Cartagena, Centro de Investigación y Docencia, Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, ³Hospital Infantil Napoleón Franco Pareja, Cartagena., Colombia
- PHS45 C2** *pgA255* **DIRECT COST OF HYPOTHYROIDISM AND ITS COMPLICATIONS IN UKRAINE**
Vadziuk I, Ivan Horbachevsky Ternopil State Medical University, Ternopil, Ukraine
- PHS46 C3** *pgA255* **CLINICAL AND ECONOMIC IMPACT OF THE INTRODUCTION OF THE VACCINE AGAINST MENINGOCOCCAL MENINGITIS C IN CHILDREN AGED 0-4 YEARS IN BRAZIL**
Andrade TR, Sansone D, Etto H, Decimoni TC, **Araujo GT**, Fonseca M, AxiaBio, São Paulo, Brazil
- PHS47 C4** *pgA255* **PATIENT RECALL FOLLOWING BREAST CANCER SCREENING MAMMOGRAPHY AMONG MEDICAID PATIENTS BY PATIENT RACE**
Bonafede MM¹, Miller JD¹, Huang A², Troeger KA³, Fajardo L⁴,¹Truven Health Analytics, Cambridge, MA, USA, ²Truven Health Analytics, Bethesda, MD, USA, ³Hologic, Inc., Marlborough, MA, USA, ⁴University of Iowa, Iowa City, IA, USA
- PHS48 C5** *pgA255* **DIRECT AND INDIRECT COSTS TO EMPLOYERS OF RECALL FOLLOWING SCREENING**

MAMMOGRAPHY AMONG FEMALE EMPLOYEES IN THE US

Bonafede MM¹, Miller JD¹, Huang A², Troeger KA³, Fajardo L⁴,¹Truven Health Analytics, Cambridge, MA, USA, ²Truven Health Analytics, Bethesda, MD, USA, ³Hologic, Inc., Marlborough, MA, USA, ⁴University of Iowa, Iowa City, IA, USA

- PHS49 C6** *pgA255* **NOVEL APPROACH TO CATEGORIZING COSTS OF PATIENTS EXPERIENCING SEIZURES**
Williams DV, Wix DA, Milliman, Windsor, CT, USA
- PHS50 C7** *pgA255* **ESTIMATING THE COST OF PNEUMONIA CASES ADMITTED AT THE INTERNAL MEDICINE WARDS OF A TERTIARY GOVERNMENT HOSPITAL IN THE PHILIPPINES**
Rivera AS, University of the Philippines Manila, Manila, Philippines
- PHS51 C8** *pgA256* **DIRECT COSTS COMPARISON OF MEDICAL CARE BEFORE AND AFTER HEART FAILURE HOSPITALIZATION IN A MEDICARE POPULATION**
Kilgore M¹, Patel H², Sharma P¹, Maya J², Kielhorn A²,¹Univeristy of Alabama at Birmingham, Birmingham, AL, USA, ²Amgen, Thousand Oaks, CA, USA
- PHS52 C9** *pgA256* **COST OF A PHARMACIST-LED PNEUMONIA EDUCATION AND IMMUNIZATION PROGRAM FOR OLDER PHILADELPHIANS**
Alcuskay MJ, Cannon-Dang E, Steele D, Schafer JJ, DeSimone Jr. JA, Pizzi LT, Thomas Jefferson University, Philadelphia, PA, USA
- PHS54 C10** *pgA256* **AN ACCESSIBLE APPROACH TO ESTIMATE THE DIRECT MEDICAL COSTS OF TYPE 2 DIABETES MELLITUS FOR THE BRAZILIAN NATIONAL HEALTH SYSTEM**
Aquino CM¹, Lima RC², Marinho MG³, Sousa IM³, Cesse EA³, Bezerra AF²,¹Federal University of Pernambuco, Recife, Brazil, ²Federal University of Pernambuco, RECIFE, Brazil, ³Oswaldo Cruz Foundation - Fiocruz, Recife, Brazil
- PHS55 C11** *pgA256* **COST ANALYSIS OF PATIENTS WITH ACUTE CORONARY EVENT IN A COMMERCIAL INSURANCE COMPANY IN COLOMBIA —SALUDCOOP— IN 2013**
Romero M¹, Torres A², Grosso G³, Urrutia C³,¹Salutia Foundation, Bogota, Colombia, ²Salutia's Foundation-Research center in economy, management and health technologies., Bogota, Colombia, ³Group SaludCoop, Bogotá, Colombia
- PHS56 C12** *pgA256* **IMPACT OF CLINICAL PHARMACIST INTERVENTIONS ON THE PRESCRIBING HABIT AND COST SAVING**
Alkhalaf MS, Dammam Medical Complex, Dammam, Saudi Arabia
- PHS59 C13** *pgA257* **COST OF REPORTING POSSIBLE ADVERSE DRUG REACTIONS IN MEDICAL OUTPATIENTS USING A TELEPHONIC INTERACTIVE VOICE RESPONSE SYSTEM**
Mahida SR¹, Seoane E¹, Klinger E², Salazar A², HER QL², Medoff J², Amato M¹, Dykes PC², Haas J², Bates D², Schiff G²,¹Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, ²Brigham and Women's Hospital, Boston, MA, USA
- PHS60 C14** *pgA257* **COST OF CANCER TREATMENT IN BRAZIL AND ITS DETERMINANTS: 2000-2003**
Cherchiglia ML¹, Perelman J², Pereira J²,¹Federal University of Minas Gerais, Belo Horizonte, Brazil, ²Universidade NOVA de Lisboa, Lisboa, Portugal
- PHS61 C15** *pgA257* **USING BIG DATA FOR AN ECONOMIC EVALUATION OF REDUCING THE INNAPPROPRIATE PRESCRIBING OF ATYPICAL ANTIPSYCHOTICS AMONG DEMENTIA PATIENTS**
Khan R, Jammali-Blasi A, Todkar A, Heaney A, NPS MedicineWise, Sydney, Australia
- PHS62 C16** *pgA257* **COST-EFFECTIVENESS OF A BEHAVIORAL PSYCHOSOCIAL TREATMENT INTEGRATED ACROSS HOME AND SCHOOL FOR PEDIATRIC ADHD-INATTENTIVE TYPE**
Tran JL, Sheng R, Esonwune-Chukwudi P, Beaulieu A, McBurnett K, Pffifner LJ, Wilson L, University of California, San Francisco, San Francisco, CA, USA
- PHS63 D1** *pgA258* **ECONOMIC EVALUATION OF A RANDOMIZED CONTROLLED TRIAL OF PHARMACIST-SUPERVISED PATIENT SELF-TESTING OF WARFARIN THERAPY**
Gallagher J, University College Cork, Cork, Ireland
- PHS64 D2** *pgA258* **COST-EFFECTIVENESS OF BREAST CANCER SCREENING IN THE NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM IN THE UNITED STATES**
Ekwueme D¹, Hoerger T², Miller J³, Allaire B², Subramanian S⁴, Sabatino S³, Royalty J³, Li C³,¹Centers for Disease Control and Prevention, Chamblee, GA, USA, ²RTI International, Research Triangle Park, NC, USA, ³US Centers for Disease Control and Prevention, Chamblee, GA, USA, ⁴RTI International, Waltham, MA, USA
- PHS65 D3** *pgA258* **COST EFFECTIVENESS OF GROUP-BASED PARENTING PROGRAMS AND BIBLIOTHERAPY FOR PARENTS OF CHILDREN AT RISK OF DEVELOPING CONDUCT DISORDER: A MULTICENTER RANDOMIZED CONTROLLED TRIAL**
Sampaio F¹, Enebrink P², Mihalopoulos C³, Feldman I¹,¹Uppsala University, Uppsala, Sweden, ²Karolinska Institute, Stockholm, Sweden, ³Deakin University, Melbourne, Australia
- PHS66 D4** *pgA258* **COST-UTILITY ASSESSMENT OF HEMODIALYSIS VERSUS DIALYSIS PERITONEAL, AS TREATMENT**

INITIAL MODALITY IN BRAZIL: A POPULATION BASE STUDY

Cherchiglia ML¹, Alvares J², Almeida AM¹, Andrade EI¹, Acurcio Fa², Andrade MV¹, Szuster DA¹, Guerra Jr AA¹, Queiroz OV¹, Gomes IC¹, Puig-Junoy J³,¹Federal University of Minas Gerais, Belo Horizonte, Brazil, ²College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil, ³Pompeu Fabra University, Barcelona, Spain

- PHS67 D5 pgA258 OUT-OF-POCKET MEDICAL COSTS FOR PARENTS WITH CHILDREN WITH DOWN SYNDROME IN THE UNITED STATES**
Kageleiry A¹, Samuelson D², Duh MS², Lefebvre P³, **DerSarkissian M**⁴, Campbell JY⁵, Skotko BG⁶,¹Analysis Group, Inc., Boston, MA, USA, ²Analysis Group, Boston, MA, USA, ³Groupe d'analyse, Itée, Montreal, QC, Canada, ⁴Analysis Group, Los Angeles, CA, USA, ⁵Harvard University, Cambridge, MA, USA, ⁶Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
- PHS68 D6 pgA258 EXPECTED COSTS AND HEALTH OUTCOMES FOR A COHORT OF ALBERTANS DIAGNOSED WITH HEPATITIS C**
Thanh NX¹, **Jacobs P**¹, Wayne A¹, Tyrrell DL², Misurski D³,¹Institute of Health Economics, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Abbvie, Chicago, IL, USA
- PHS69 D7 pgA259 ESTIMATING HEALTHCARE RESOURCE USE ASSOCIATED WITH THE TREATMENT OF METASTATIC MELANOMA IN EIGHT COUNTRIES**
McKendrick J¹, Gijssen M¹, **Quinn C**¹, Zhao Z², Barber BL²,¹PRMA Consulting, Fleet, UK, ²Amgen Inc, Thousand Oaks, CA, USA
- PHS70 D8 pgA259 ASSOCIATION OF CHANGE IN FORCED VITAL CAPACITY WITH HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH NEWLY DIAGNOSED IDIOPATHIC PULMONARY FIBROSIS**
Reichmann WM¹, Yu Y², Macaulay D³, Nathan SD⁴,¹Analysis Group, Inc., Boston, MA, USA, ²Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, ³Analysis Group, Inc., New York, MA, USA, ⁴Inova Heart and Vascular Institute, Falls Church, VA, USA
- PHS71 D9 pgA259 BURDEN OF MELANOMA AMONG ADULTS ENROLLED IN MEDICAID PROGRAM**
Shah R, Khanna R, Pace P, Banahan III B, University of Mississippi, University, MS, USA
- PHS72 D10 pgA259 EXPANSION OF CURRENT HPV VACCINATION GUIDELINES TO INCLUDE MEN WHO HAVE SEX WITH MEN WHO ARE 27 YEARS OR OLDER – A VALUE OF INFORMATION ANALYSIS**
Deshmukh AA¹, Cantor SB¹, Chiao EY², Nyitray AG³, Das P¹, Chhatwal J¹,¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA, ²Baylor College of Medicine, Houston, TX, USA, ³The University of Texas School of Public Health, Houston, TX, USA

HEALTH SERVICES - Patient-Reported Outcomes & Patient Preference Studies

- PHS73 D11 pgA259 IMPACT OF EMAIL REFILL REMINDERS ON MEDICATION ADHERENCE AMONG PATIENTS WITH CHRONIC DISEASES IN A RETAIL COMMUNITY PHARMACY**
Taitel MS, Mu Y, **Lou Y**, Cannon A, Walgreen Co., Deerfield, IL, USA
- PHS74 D12 pgA260 IMPACT OF APPOINTMENT-BASED MEDICATION SYNCHRONIZATION ON EXISTING USERS OF CHRONIC MEDICATIONS**
Holdford DA, **Saxena K**, Virginia Commonwealth University, Richmond, VA, USA
- PHS75 D13 pgA260 EXAMINING THE IMPACT OF A HYBRID CLINICAL PHARMACY PRACTICE MODEL ON MEDICATION ADHERENCE IN PATIENTS WITH METABOLIC SYNDROME**
Pinto S, **Hastings TJ**, Bechtol R, Vaidya V, Khuder S, University of Toledo, Toledo, OH, USA
- PHS76 D14 pgA260 THREE METHODS TO ASSESS ADHERENCE TO HIV ANTIRETROVIRAL TREATMENT IN A CHILEAN HEALTHCARE SETTING**
San Martin B¹, Lopez M², Cordova P², Fernandez P², Morales F², **Villa L**²,¹Hospital Chiloe, Chiloe, Chile, ²Facultad de Farmacia, Universidad de Concepción, Concepción, Chile
- PHS77 D15 pgA260 PHARMACOTHERAPY OPTIMIZATION PLAN FOR PATIENTS WITH TYPE-2 DIABETES MELLITUS (T2DM) AND HYPERTENSION IN A CHILEAN HEALTHCARE SETTING: IMPACT AND OUTCOMES**
Soto A¹, Avila X², Cordova P³, Fernandez P³, Lopez M³, **Villa LA**³, Morales F³,¹CESFAM Bicentenario, Arauco, Chile, ²San Vicente Hospital, Arauco, Chile, ³Facultad de Farmacia, Universidad de Concepción, Concepción, Chile
- PHS78 D16 pgA260 DEVELOPMENT AND VALIDATION OF PATIENT DECISION AID REGARDING ANTIDEPRESSANT MEDICATIONS.**
al Jumah ka¹, Hassali AA²,¹MOH, Riyadh, Saudi Arabia, ²Universiti Sains Malaysia, Penang, Malaysia
- PHS79 E1 pgA260 IMPACT OF STRUCTURED PATIENT EDUCATION ON QUALITY OF LIFE OF SOUTH INDIAN DIABETICS**
Talla V¹, Yellu NR², Pippalla SR³, Rao V¹, Pattnaik S¹, Subudhi S⁴, Budike R¹, Pandalaneni A³,¹Talla Padmavathi College of Pharmacy, Warangal, INDIA, WARANGAL, India, ²UNIVERSITY COLLEGE OF PHARMACEUTICAL SCIENCES, KAKATIYA UNIVERSITY, WARANGAL, India, ³TALLA PADMAVATHI COLLEGE OF PHARMACY, WARANGAL, India, ⁴Talla Padmavathi Pharmacy College, Warangal, WARANGAL, India
- PHS80 E2 pgA261 A VISION 'BOLT-ON' ITEM INCREASED THE SENSITIVITY OF EQ-5D IN A CROSS-SECTIONAL HEALTH**

SURVEY

Wang X¹, Ang M², Finkelstein EA³, Aung T², Wong TY², Lamoureux E³, Luo N^{4,1}, National University of Singapore, Singapore, Singapore, Singapore, ²Singapore National Eye Center, Singapore, Singapore, Singapore, ³Duke-NUS Graduate Medical School, Singapore, Singapore, Singapore, ⁴Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, Singapore

- PHS81 E3 pgA261 LEAN WORKFLOW CHANGES MAY CONTRIBUTE TO IMPROVED PRIMARY CARE PATIENT SATISFACTION**
Chen P, Palo Alto Medical Foundation, Mountain View, CA, USA
- PHS82 E4 pgA261 DESCRIPTION OF PATIENTS SATISFACTION OR DISSATISFACTION WITH REFERRAL AND COUNTER REFERRAL PROCESS**
Mogere DM, Loum CS, Kaseje D, Great Lakes University of Kisumu, Nairobi, Kenya
- PHS83 E5 pgA261 TUBERCULOSIS SCREENING PREFERENCES OF HEALTHCARE WORKERS IN SOUTH AFRICA: A BEST-WORST SCALING STUDY TO ANALYZE VARIATION BY OCCUPATION**
O'Hara NN¹, Roy L¹, O'Hara LM¹, Spiegel JM¹, Lynd LD¹, FitzGerald JM¹, Yassi A¹, Nophale LE², Marra CA^{3,1}, University of British Columbia, Vancouver, BC, Canada, ²University of the Free State, Bloemfontein, South Africa, ³Memorial University, St. John's, NF, Canada
- PHS84 E6 pgA261 SHARED DECISION MAKING DOES NOT IMPROVE ADHERENCE TO PROSTATE CANCER SCREENING: EVIDENCE FROM THE HEALTH INFORMATION NATIONAL TREND SURVEY**
Haider MR¹, Qureshi Z¹, Horner R¹, Bennett C², Khan MM^{3,1}, University of South Carolina, Columbia, SC, USA, ²University of South Carolina College of Pharmacy, Columbia, SC, USA, ³University of South Carolina, COLUMBIA, SC, USA
- PHS85 E7 pgA261 HEALTH RELATED QUALITY OF LIFE AND HEALTH CARE RESOURCE USE BURDEN IN MIGRAINE WITH AND WITHOUT NAUSEA**
Flores NM¹, Lee LK¹, **Gajria K²**, Pomerantz D³, Gandhi SK^{2,1}, Kantar Health, Foster City, CA, USA, ²Teva Pharmaceuticals Inc, Malvern, PA, USA, ³Kantar Health, Horsham, PA, USA
- PHS86 E8 pgA262 DO DEPRESSION RATES DIFFER BY CONFLICT ERA AMONG WAR VETERANS?**
Adjei Boakye E, Stringer LR, Geneus C, Tobo BB, Buchanan P, Saint Louis University, Saint Louis, MO, USA
- PHS87 E9 pgA262 PATIENT REPORTED OUTCOMES REVEAL DISCORDANCE BETWEEN PATIENT AND PHYSICIAN ASSESSMENT OF DISEASE BURDEN IN PATIENTS WITH RHEUMATOID ARTHRITIS**
Feinberg BA¹, Lal L², Mujumdar U¹, Olson T³, Baraf HS⁴, Matsumoto AK^{4,1}, Cardinal Health, Dublin, OH, USA, ²Cardinal Health, Missouri City, TX, USA, ³Cardinal Health, Minneapolis, MN, USA, ⁴Arthritis and Rheumatism Associates, Wheaton, MD, USA
- PHS88 E10 pgA262 FEASIBILITY OF REAL-TIME COLLECTION OF PATIENT REPORTED OUTCOMES AT POINT OF CARE**
Feinberg BA¹, Baraf HS², Matsumoto AK², Olson T³, Mujumdar U^{1,1}, Cardinal Health, Dublin, OH, USA, ²Arthritis and Rheumatism Associates, Wheaton, MD, USA, ³Cardinal Health, Minneapolis, MN, USA
- PHS89 E11 pgA262 IMPACT OF PATIENT REPORTED OUTCOMES ON MEDICATION THERAPY MANAGEMENT FOR HIGH-COST SPECIALTY DRUGS**
Feinberg BA¹, Burruss R², Traurig T², Drenning J^{3,1}, Cardinal Health, Dublin, OH, USA, ²OncoSource Rx, Columbia, MD, USA, ³Cardinal Health, Dallas, TX, USA
- PHS90 E12 pgA262 GEOGRAPHIC PATTERNS OF SELF-REPORTED LIFETIME DEPRESSION DIAGNOSIS**
Tobo BB, Adjei Boakye E, Buchanan P, Saint Louis University, Saint Louis, MO, USA
- PHS91 E13 pgA263 [EVALUATION OF THE QUALITY OF LIFE OF DIABETIC PATIENTS IN MINAS GERAIS STATE, BRAZIL]**
Mata AR¹, Ferreira Ha¹, **Alvares J¹**, Silva MR¹, Araujo VE¹, Diniz LM², Acurcio Fa^{1,1}, College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil, ²Medical College, Federal University of Minas Gerais, Belo Horizonte, Brazil

HEALTH SERVICES - Health Care Use & Policy Studies

- PHS92 E14 pgA263 PREDICTORS OF MAMMOGRAPHY SCREENING AMONG WOMEN AGED 50-74**
Nduaguba O, **Sudhapalli P**, Barner J, The University of Texas at Austin, Austin, TX, USA
- PHS93 E15 pgA263 DISCUSSION BETWEEN PROVIDERS AND PATIENTS ABOUT PROSTATE SPECIFIC ANTIGEN TESTING IN USA**
Mukherjee K¹, Segal R^{2,1}, Chicago State University, Chicago, IL, USA, ²University of Florida, Gainesville, IL, USA
- PHS94 E16 pgA263 LONG-TERM IMPACT OF A PHARMACIST-LED DIABETES MEDICATION MANAGEMENT PROGRAM ON GLYCEMIC CONTROL**
Tran M¹, Godley P², Stock EM³, Rascati KL⁴, Tabor PA^{2,1}, Scott & White Health Plan, Austin, TX, USA, ²Scott & White Health Plan, Temple, TX, USA, ³Center for Applied Health Research - Central Texas Veterans Health Care System jointly with Baylor Scott & White Health, Temple, TX, USA, ⁴The University of Texas at Austin, College of Pharmacy, Austin, TX, USA
- PHS95 F1 pgA263 ASSESSING A PHYSICIAN VISIT FOR HEPATIC DYSFUNCTION BASED ON DATABASE MERGING CLAIMS AND ANNUAL HEALTH CHECKUP DATA IN JAPAN**

- Ito C¹, Nishikino R¹, **Onishi Y**^{2,1}, JMDC Co., Ltd., Tokyo, Japan, ²Creativ-Ceutical K.K., Tokyo, Japan
- PHS96 F2** *pgA263* **RELATIVE AGE IN CLASS AND ADHD IN SCHOOL CHILDREN – DIAGNOSIS AND MEDICATION PATTERNS – INTRA-ANNUAL AND INTER-ANNUAL DISPARITY**
Hoshen MB¹, Benis A², Keyes KM³, Zoega H⁴, ¹Clalit Research Institute, Tel Aviv, Israel, ²Clalit Health Services, Tel Aviv, Israel, ³Columbia University, New York, NY, USA, ⁴University of Iceland, Reykjavík, Iceland
- PHS97 F3** *pgA264* **SPECIALTY PHARMACY MEDICATION COMPLIANCE AND PERSISTENCE PROGRAM FOR PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION**
D'Albini L¹, Tian Y², Raspa S³, Drake W⁴, ¹Accredo, Spring Hill, KS, USA, ²Express Scripts, St. Louis, MO, USA, ³Actelion Pharmaceuticals US, Inc., South San Francisco, CA, USA, ⁴Actelion Pharmaceuticals, US, Inc., South San Francisco, CA, USA
- PHS98 F4** *pgA264* **DO PHARMACISTS' BARRIERS—INCLUDING NON-REIMBURSEMENT FOR NON-DISPENSING SERVICES—INFLUENCE THE LEVEL OF ADHERENCE PROMOTION ACTIVITIES FOR PERSONS LIVING WITH HIV?**
Kibicho J, University of Wisconsin-Milwaukee, Milwaukee, WI, USA
- PHS99 F5** *pgA264* **REGISTRY ADOPTED AS PUBLIC POLICY FOR PROPER RISK MANAGEMENT IN CHRONIC KIDNEY DISEASE IN COLOMBIA**
Acuna L, Sanchez P, Soler L, cuenta de alto costo, bogota, Colombia
- PHS101 F6** *pgA264* **HEALTHCARE RESOURCE USE AMONG PATIENTS WITH CONGESTIVE HEART FAILURE IN A LARGE HEALTH ORGANIZATION**
Bash LD¹, Weitzman D², Sharon O³, Aviram-Paz M⁴, Chodick G⁵, Shalev V^{2,1}, Merck and Co., Inc., Rahway, NJ, USA, ²Maccabitech, Maccabi Health Care Services and Tel Aviv University, Tel Aviv, Israel, ³MSD Israel, Hod Hasharon, Israel, ⁴Tel Aviv University, Tel Aviv, Israel, ⁵Maccabi Healthcare Services and Tel Aviv University, Tel Aviv, Israel
- PHS102 F7** *pgA265* **WILL U.S. PAYERS CHAMPION BIOSIMILARS?**
Malik AN, Cox J, Keeping K, Decision Resources Group, London, UK
- PHS103 F8** *pgA265* **ARE GENERIC MEDICINES GOOD FOR MY PATIENTS? FINDINGS FROM A QUALITATIVE ASSESSMENT OF PERCEPTIONS AMONG MEDICAL SPECIALISTS IN MALAYSIA**
Zhi Yen W¹, Hassali MA², Alrasheedy AA³, Saleem F⁴, Mohamad Yahaya AH¹, Aljadhey H⁵, ¹Hospital Teluk Intan, Teluk Intan, Perak, Malaysia, ²Universiti Sains Malaysia (USM), Pulau Pinang, Malaysia, ³Qassim University, Almulyda, Saudi Arabia, ⁴Universiti Sains Malaysia, Penang, Malaysia, ⁵King Saud University, Riyadh, Saudi Arabia
- PHS104 F9** *pgA265* **PROTON PUMP INHIBITOR PRESCRIBING TREND IN THE US AMBULATORY SETTING**
Rane P¹, Aparasu RR¹, Guha S^{2,1}, University of Houston, Houston, TX, USA, ²University of Texas Health Science Center, Houston, TX, USA
- PHS105 F10** *pgA265* **IMPORTANCE OF JOINT WORK BETWEEN PHARMACIST AND PHYSICIAN IN THE RATIONAL DRUG USE IN PATIENTS WITH OSTEOPOROSIS,**
Estrada JI¹, Galvis MJ², Caro M³, Abad JM¹, Segura AM^{4,1}, CES University, Medellin, Colombia, ²Nacional University, Bogota, Colombia, ³Antioquia University, Bogota, Colombia, ⁴Antioquia University, Medellin, Colombia
- PHS107 F12** *pgA265* **PREVALENCE AND DETERMINANTS OF LOW-COST GENERIC DRUG PROGRAM USE IN THE PRIVATELY-INSURED ADULT POPULATION**
Pauly N, Brown J, University of Kentucky, Lexington, KY, USA
- PHS108 F13** *pgA266* **SOCIOECONOMIC DIFFERENTIAL IN ONE-YEAR SURVIVAL AFTER HOSPITALIZATION FOR ISCHEMIC STROKE: THE EFFECT OF ACUTE AND POST-ACUTE CARE-PATHWAYS IN LAZIO REGION, ITALY**
Belleudi V, Sciattella P, Agabiti N, Di Martino M, Di Domenicantonio R, Davoli M, Fusco D, Department of Epidemiology of the Regional Health Service - Lazio, ROME, Italy
- PHS109 F14** *pgA266* **GENDER DISTRIBUTION OF OUTPATIENT CARE PHYSIOTHERAPY SERVICES FOR LOW BACK PAIN IN HUNGARY**
Járomi M¹, Hanzel A¹, Rátgéber L², Juhász K³, Sebestyén A¹, **Boncz I**¹, Csákvári T⁴, Vajda R¹, Molics B¹, ¹University of Pécs, Pécs, Hungary, ²Ratgeber Academia, Pécs, Hungary, ³National Health Insurance Fund Administration, Pécs, Hungary, ⁴University of Pécs, Zalaegerszeg, Hungary
- PHS110 F15** *pgA266* **REFERRAL RECOMMENDATIONS MADE BY COMMUNITY HEALTH WORKERS ON THE 'PATIENTS' REFERRAL SLIPS. BRIDGING HOUSEHOLDS TO SUSTAINABLE HEALTHCARE; KENYAN EXPERIENCE**
Mogere DM, Loum CS, Kaseje D, Great Lakes University of Kisumu, Nairobi, Kenya
- PHS111 F16** *pgA266* **FREQUENT EMERGENCY DEPARTMENT USE AMONG NON-ELDERLY ADULTS: ANALYSIS OF MULTI-STATE MEDICAID CLAIMS DATA**
Agarwal P¹, Bias T¹, Frisbee S¹, Sambamoorthi N², Bose S¹, Madhavan SS¹, Sambamoorthi U¹, ¹West Virginia University, Morgantown, WV, USA, ²Northwestern University, Chicago, IL, USA
- PHS112 G1** *pgA266* **HUMAN PAPILLOMAVIRUS (HPV) VACCINATION DURING WELL-CHILD VISITS IN PRIVATELY INSURED MALES 9-21 YEARS OF AGE IN THE UNITED STATES IN 2012**

Zhang D¹, Huang M², **Kulkarni AS**³, Niccolai LM⁴,¹Merck & Co., Inc., West Point, PA, USA, ²Merck & Co. Inc (under contract with Agile-1), West Point, PA, USA, ³Merck & Co. Inc, Rahway, NJ, USA, ⁴Yale School of Public Health, New Haven, CT, USA

- PHS114 G2** *pgA267* **AGE AND GENDER DISTRIBUTION OF OUTPATIENT CARE PHYSIOTHERAPY SERVICES FOR SHOULDER AND UPPER ARM INJURIES IN HUNGARY**
Molics B¹, **Boncz I**¹, Endrei D¹, Rátgéber L², Juhász K³, Sebestyén A³, Vajda R¹, Csákvári T⁴, Járomi M¹,¹University of Pécs, Pécs, Hungary, ²Ratgeber Academia, Pécs, Hungary, ³National Health Insurance Fund Administration, Pécs, Hungary, ⁴University of Pécs, Zalaegerszeg, Hungary
- PHS115 G3** *pgA267* **HEALTHCARE COVERAGE, EXPENDITURES AND POPULATION HABITS IN ARGENTINA**
Najun Dubos L, Cuberos M, Benitez J,Roche Argentina, Buenos Aires, Argentina
- PHS116 G4** *pgA267* **THE IMPACT OF NCMS POLICIES ON INPATIENT HEALTH EXPENDITURE AND ITS EQUALITY IN RURAL CHINA**
Guo N¹, Wang J², Shi LW³, Han S³, Zhu D⁴, Guan XD³,¹Department of Pharmaceutical Science,Peking University, Beijing, China, ²Shandong University, Jinan, China, ³International Research Center of Medical Administration, Peking University, Beijing, China, ⁴Center for Health Policy and Management, Institute of Medical Information & Library, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
- PHS117 G5** *pgA267* **REDUCING MATERNAL AND CHILD MORTALITY IN GHANA: IS NATIONAL HEALTH INSURANCE SCHEME'S FREE MATERNAL CARE PROGRAMME HELPING?**
Nsiah-Boateng E,National Health Insurance Authority, Accra, Ghana
- PHS118 G6** *pgA267* **DEFINITION OF END-OF-LIFE PERIOD AND QUALITY BENCHMARKS IN TERMINAL CANCER CARE: A LITERATURE REVIEW**
Sieluk J¹, Goto D¹, Hanna N², Mullins CD¹,¹University of Maryland School of Pharmacy, Baltimore, MD, USA, ²University of Maryland Department of Surgery, Division of General and Oncologic Surgery, Baltimore, MD, USA
- PHS119 G7** *pgA267* **THE IMPACT OF PATIENT CENTERED MEDICAL HOME IN A MANAGED MEDICAID POPULATION**
Chu L,University of Southern California, Los Angeles, CA, USA
- PHS120 G8** *pgA268* **PREVENTING CERVIX-UTERUS CANCER IN ARGENTINA. STRUCTURE, ORGANIZATION AND RESULTS**
Maceira D,Center for the Study of State and Society (CEDES), Buenos Aires, Argentina
- PHS121 G9** *pgA268* **A NOVEL STILLBIRTH AUDIT TOOL IMPLEMENTATION IN GHANA: ASSESSMENT OF DEPLOYMENT IN 2014**
Davies-Teye BB¹, Baison HM², Oduro-Mensah E³, Vanotoo L²,¹Drifney Consult Ltd, Accra, Ghana, ²Greater Accra Regional Health Directorate Ghana Health Services, Accra, Ghana, ³Ridge Hospital OPD, Accra, Ghana
- PHS123 G10** *pgA268* **DIFFERENCES IN BREAST CANCER SCREENING RATES IN MEDICARE ADVANTAGE NON-DUAL ELIGIBLE MEMBERS, DUAL ELIGIBLES ENROLLED IN SPECIAL NEED PLANS AND OTHER HEALTHCARE PLANS**
Pulungan Z, Teigland C, Mehta S, Parente A,Inovalon, Bowie, MD, USA
- PHS124 G11** *pgA268* **DIFFERENCES IN CHARACTERISTICS, HEALTH SERVICE UTILIZATION AND COST BETWEEN OLDER HOSPITALIZED LUNG CANCER PATIENTS WITH OR WITHOUT ASTHMA**
Roy D¹, Blanchette CM², Zacherle E²,¹University of North Carolina, Charlotte, Charlotte, NC, USA, ²University of North Carolina at Charlotte, Charlotte, NC, USA
- PHS125 G12** *pgA268* **POTENTIAL SAVINGS IN HEALTHCARE SPENDING ON "LOW-VALUE" INTERVENTIONS: CASE STUDY OF ARTHROSCOPIC KNEE SURGERY**
Rane PB¹, Olchanski N¹, Saret CJ¹, Cohen JT¹, Neumann PJ²,¹Center for the Evaluation of Value and Risk in Health,Tufts Medical Center, Boston, MA, USA, ²Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies,Tufts Medical Center, Boston, MA, USA
- PHS126 G13** *pgA268* **IS VISUAL IMPAIRMENT ASSOCIATED WITH INCREASED HOSPITALIZATION? A RETROSPECTIVE COHORT STUDY OF COMMUNITY-DWELLING MEDICARE BENEFICIARIES**
Tsang Y, Tom S, Onukwugha E,University of Maryland School of Pharmacy, Baltimore, MD, USA
- PHS127 G14** *pgA269* **HEALTH SERVICES UTILIZATION AND COSTS AMONG EMPLOYED ADULTS WITH DEPRESSION**
Gangan N, Yang Y,University of Mississippi, University, MS, USA
- PHS128 G15** *pgA269* **MEDICAL RESOURCE UTILIZATION OF ACUTE MYOCARDIAL INFARCTION PATIENTS WITH READMISSION: A RETROSPECTIVE ANALYSIS OF HOSPITALIZATION DATA FROM BEIJING MEDICAL INSURANCE DATABASE**
Wen L¹, Wu J², **Yang L**¹,¹Peking University, Beijing, China, ²Bayer, Beijing, China
- PHS129 G16** *pgA269* **EFFECTS OF OVERWEIGHT AND OBESITY ON HEALTH SERVICE USE AND EXPENDITURES AMONG U.S. ADULTS WITH CHRONIC RENAL DISEASE**
Zanwar P¹, Franzini L²,¹University of Houston Clear Lake, Houston, TX, USA, ²University of Maryland School of Public Health, College Park,, MD, USA
- PHS130 G17** *pgA269* **PREDICTING MEDICAL REIMBURSEMENT AMOUNT - WHAT FACTORS DRIVE THE MEDICAL COST**

TREND

Wang QC, Sickler A, Chawla R, Nigam S, Independence Blue Cross, Philadelphia, PA, USA

PHS131 G18 pgA269 **OUT-OF-POCKET HEALTHCARE EXPENDITURES AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE**

Kang HA, Barner JC, The University of Texas at Austin, Austin, TX, USA

PHS132 G19 pgA269 **COST STUDY ON PROVINCIAL GENERAL HOSPITALS**

Gantugs Y¹, Otgonbayar D², Tsolmongerel T³,¹Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia, ²Mongolian Medical Education Association, Ulaanbaatar, Mongolia, ³MOH, Ulaanbaatar, Mongolia

PHS133 G20 pgA270 **MEDICAL RESOURCE UTILIZATION OF ISCHEMIC STROKE PATIENTS WITH READMISSION: A RETROSPECTIVE ANALYSIS OF HOSPITALIZATION DATA FROM BEIJING MEDICAL INSURANCE DATABASE**

Wen L¹, Wu J², **Yang L**¹,¹Peking University, Beijing, China, ²Bayer, Beijing, China

PHS134 G21 pgA270 **THE MARKET FOR HEPATITIS C SERVICES IN ALBERTA**

Thanh NX¹, Misurski D², Waye A¹, **Jacobs P**¹, Tyrrell DL³,¹Institute of Health Economics, Edmonton, AB, Canada, ²Abbvie, Chicago, IL, USA, ³University of Alberta, Edmonton, AB, Canada

PHS135 H1 pgA270 **COST OF PRIMARY AND SECONDARY HEALTHCARE UTILIZATION FOR PATIENTS WITH IRRITABLE BOWEL SYNDROME CALCULATED USING ROUTINELY COLLECTED ELECTRONIC RECORDS TO ASSESS THE IMPACT OF SECONDARY CARE REFERRAL**

Canavan C, Card T, West J, University of Nottingham, Nottingham, UK

PHS136 H2 pgA270 **UTILIZATION AND PAYMENT OF ERCP-RELATED OPERATIONS AND MEDICAL SUPPLIES IN CHINA BMI INPATIENTS**

Cui B¹, Wang L², Xiong X², Li J²,¹Peking University, Beijing, China, ²China Health Insurance Research Association, Beijing, China

PHS138 H3 pgA270 **COLORECTAL CANCER (CRC) COSTS IN THE US: FINDINGS FROM THE MEDICAL EXPENDITURE PANEL SURVEY 2008-2012**

Haider MR¹, Qureshi Z¹, Horner R¹, Xirasagar S¹, Khan MM²,¹University of South Carolina, Columbia, SC, USA, ²University of South Carolina, COLUMBIA, SC, USA

PHS139 H4 pgA271 **PREDICTORS AND TRENDS IN UTILIZATION OF CERVICAL CANCER PREVENTIVE CARE SERVICES IN THE U.S**

Gunjal SS¹, **Wang X**², Mgbere O³, Essien EJ²,¹Precision Health Economics, Austin, TX, USA, ²University of Houston, Houston, TX, USA, ³Houston Department of Health and Human Services, Houston, TX, USA

PHS140 H5 pgA271 **PATIENT RACE/ETHNICITY, PERCEIVED QUALITY OF HEALTHCARE AND HOSPITALIZATIONS: AN INVESTIGATION USING THE MEDICAL EXPENDITURE PANEL SURVEY**

Ampaabeng SK¹, Onukwugha E²,¹IMPAQ International, Columbia, MD, USA, ²University of Maryland School of Pharmacy, Baltimore, MD, USA

PHS141 H6 pgA271 **POINT-OF-CARE, REAL-TIME DECISION SUPPORT TOOLS: A PATHWAY COMPLIANCE SOLUTION BUT ONLY WHEN THEY ARE USED**

Feinberg BA¹, Laney J², English S³, Drenning J⁴,¹Cardinal Health, Dublin, OH, USA, ²Cardinal Health, Locust Grove, GA, USA, ³Cardinal Health, Conyers, GA, USA, ⁴Cardinal Health, Dallas, TX, USA

PHS142 H7 pgA271 **STATUS OF BIRTHS MADE WITHIN SUS IN BRAZIL**

Sansone D, Etto H, Andrade TR, Araujo GT, **Fonseca M**, AxiaBio, São Paulo, Brazil

PHS143 H8 pgA271 **IMPACT OF MEDICATION THERAPY MANAGEMENT (MTM) PILOT PROGRAM ON HEALTHCARE UTILIZATION AND COSTS AMONG TEXAS MEDICAID PATIENTS WITH HYPERTENSION**

Makhinova T¹, Barner JC¹, Lawson KA¹, Roberson K²,¹The University of Texas at Austin, Austin, TX, USA, ²Texas Pharmacy Association, Austin, TX, USA

PHS144 H9 pgA271 **CHARACTERISTICS OF DRUG THERAPY PROBLEMS AND RESPONSE RATE IN TELEPHONIC COMPREHENSIVE MEDICATION REVIEWS PROVIDED TO 2014 MEDICARE PART D BENEFICIARIES**

Wong J, Scott and White Health Plan, Temple, TX, USA

PHS145 H10 pgA272 **IDENTIFYING KEY FACTORS FOR TARGETING PATIENTS MOST SUITABLE FOR COMMUNITY HEALTH WORKER PROGRAM**

Wang QC, **Nandyala P**, Chawla R, Nigam S, Independence Blue Cross, Philadelphia, PA, USA

PHS146 H11 pgA272 **EVALUATION OF A PRE HOSPITAL CARE PROGRAM FOR PATIENTS WITH TRIAGE III-IV**

Romero M¹, Torres A², Barrios E³, Villegas J³, Lee J³,¹Salutia Foundation, Bogota, Colombia, ²Salutia's Foundation- Research center in economy, management and health technologies., Bogota, Colombia, ³Cooemeva Group, Cali, Colombia

PHS147 H12 pgA272 **IMPACT OF A COMMUNITY PHARMACY-BASED TRANSITION OF CARE PROGRAM ON HOSPITAL READMISSIONS AT 30 AND 180 DAYS**

Ni W¹, Colayco D², McCombs J¹,¹University of Southern California, Los Angeles, CA, USA, ²Komoto Healthcare, Bakersfield, CA, USA

- PHS149 H13** *pgA272* **USE OF PRESCRIPTION MONITORING PROGRAMS BY PRIMARY CARE PHYSICIANS: RESULTS OF A NATIONAL SURVEY**
Hwang CS¹, Rutkow L², Turner L², Lucas E², Alexander GC³,¹Food and Drug Administration, Silver Spring, MD, USA, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, ³Johns Hopkins School of Public Health, Center for Drug Safety and Effectiveness, Baltimore, MD, USA
- PHS150 H14** *pgA272* **COMPARISON OF GUIDELINES AND MANAGEMENT FOR GASTRIC CANCER SCREENING BETWEEN KOREA AND JAPAN**
Hamashima C¹, Kim Y², Choi KS²,¹National Cancer Center, Tokyo, Japan, ²National Cancer Control Institute, Gyeonggi-do, South Korea
- PHS151 H15** *pgA272* **IMPACT OF CASE MANAGEMENT NURSES ON CANCER PATIENTS: A SYSTEMATIC REVIEW**
Bregman C¹, Doutriaux A², Cagnet M², Gauthier A², Pourcel G³, Ferrari C³, Viguier J³,¹Amaris, Paris, France, ²Amaris, London, UK, ³Institut National du Cancer, Boulogne Billancourt, France
- PHS152 H16** *pgA273* **AN INNOVATIVE CLOUD-BASED PLATFORM FOR IMPLEMENTING PERFORMANCE-BASED RISK-SHARING ARRANGEMENTS (PBRAS) IN ONCOLOGY SETTINGS**
De Rosa M¹, Martini N², Ortali M¹, Esposito I², Roncadori A¹,¹CINECA Interuniversity Consortium, Casalecchio di Reno, Italy, ²Accademia Nazionale di Medicina, Roma, Italy
- PHS153 H17** *pgA273* **SOCIOECONOMIC INEQUALITIES IN PRENATAL CARE UTILIZATION IN PAKISTAN**
Jahangeer RA,Pakistan Institute of Development Economics (PIDE), Islamabad, Pakistan
- PHS154 H18** *pgA273* **ESTIMATING THE HEALTH BENEFITS OF MEETING THE HEALTHY PEOPLE 2020 OBJECTIVES FOR REDUCING INVASIVE COLORECTAL CANCER INCIDENCE IN THE UNITED STATES**
Hung M¹, Ekwueme D², Wang J³,¹Division of Cancer Prevention and Control, US Centers for Disease Control and Prevention, Chamblee, GA, USA, ²Centers for Disease Control and Prevention, Chamblee, GA, USA, ³Department of Public Health, National Cheng Kung University College of Medicine, Tainan, Taiwan
- PHS155 H19** *pgA273* **MORAL HAZARD AND HEALTH INSURANCE: EXAMINING THE ROLE OF PRIVATE VS. PUBLIC INSURANCE IN PROSTATE CANCER SCREENING, PROSTATE CANCER DIAGNOSIS AND PATIENT SATISFACTION WITH PROSTATE CANCER CARE**
Zanwar P,University of Houston Clear Lake, Houston, TX, USA
- PHS156 H20** *pgA273* **HEALTHCARE BURDEN OF CERVICAL CANCER IN A NATIONAL MEDICAID MANAGED CARE POPULATION**
Joshi N, Khanna R, Pace P, Banahan III B,University of Mississippi, University, MS, USA
- PHS157 H21** *pgA274* **NONCOMMUNICABLE DISEASE PREVENTION AND CONTROL IN MONGOLIA: A POLICY ANALYSIS**
Chimedamba O¹, Peeters A², Walls H³, Joyce C¹,¹School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia, ²Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia, ³London School of Hygiene and Tropical Medicine, London, UK
- PHS158 I1** *pgA274* **FACTORS PREDICTING RECEIPT OF PROSTATE SPECIFIC ANTIGEN (PSA) TESTING: EVIDENCE FROM THE NATIONAL AMBULATORY MEDICAL CARE SURVEY (NAMCS) DATA**
Haider MR¹, Qureshi Z¹, Horner R¹, Bennett C²,¹University of South Carolina, Columbia, SC, USA, ²University of South Carolina College of Pharmacy, Columbia, SC, USA
- PHS159 I2** *pgA274* **THE BURDEN OF GOUT IN A CANADIAN PRIMARY CARE POPULATION**
Williams DM¹, Cowan C¹, Gendron A¹, Goodfield J², Oraichi D², Fischer A², Borrelli R², Liu N², Dziarmaga A¹,¹AstraZeneca Canada Inc., Mississauga, ON, Canada, ²IMS Brogan, Mississauga, ON, Canada
- PHS160 I3** *pgA274* **EVALUATING THE PREVALENCE OF MENINGITIS IN HAZARA DIVISION, KPK PAKISTAN**
Azhar SA, Khan GN, Wazir FW, Izhar IH,COMSATS Institute of Information Technology, Abbottabad, Pakistan
- PHS161 I4** *pgA274* **RECENT TRENDS IN BACTERIAL INFECTION-RELATED HOSPITALIZATIONS IN THE US**
Kurosky SK, Reese ES, Candrilli S,RTI Health Solutions, Research Triangle Park, NC, USA
- PHS162 I5** *pgA274* **PREVALENCE OF MENTAL HEALTH DISORDERS AND ACCESS TO CARE AMONG CHILDREN ENROLLED IN THE MISSISSIPPI MEDICAID**
Nunna S¹, Shah R¹, Banahan III B¹, Hardwick SP², Clark JP²,¹University of Mississippi, University, MS, USA, ²Mississippi Division of Medicaid, Jackson, MS, USA
- PHS163 I6** *pgA275* **IS THE UPTAKE OF VOLUNTARY MEDICAL MALE CIRCUMCISION INFLUENCED BY LEVEL OF EDUCATION, MARITAL STATUS AND MAIN SOURCE OF INCOME? CASE STUDY OF WESTERN KENYA**
Mogere DM,Great Lakes University of Kisumu, Nairobi, Kenya
- PHS165 I7** *pgA275* **IMPACT OF COMMUNITY BASED THERAPY ON CHILDREN WITH MENTAL HEALTH DISORDERS: A HEALTH TECHNOLOGY ASSESSMENT**
Chahar A¹, Gulati R¹, Sharma J¹, Likhari N², Dang A²,¹National Health Systems Resource Centre, Division of Healthcare Technology, New Delhi, India, ²MarksMan Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India
- PHS166 I8** *pgA275* **INCREASING HOUSEHOLDS' ACCESS TO HEALTHCARE; LINKING CLINICIANS TO COMMUNITY HEALTH WORKERS THROUGH COUNTER REFERRAL COMMENTS**

- Mogere DM**, Loum CS, Kaseje D, Great Lakes University of Kisumu, Nairobi, Kenya
- PHS167 I9 pgA275 **ARE EVIDENCE-BASED PRACTICES ASSOCIATED WITH EFFECTIVE PREVENTION OF HOSPITAL-ACQUIRED PRESSURE ULCERS IN U.S. HOSPITALS?**
Padula W¹, Gibbons RD¹, Valuck RJ², Makic MB², Meltzer D¹,¹University of Chicago, Chicago, IL, USA, ²University of Colorado, Aurora, CO, USA
- PHS168 I10 pgA275 **ANTIPSYCHOTIC MEDICATION USE MEASURES FOR CHILDREN AND ADOLESCENTS: METABOLIC SCREENING FOR CHILDREN ON ANTIPSYCHOTICS**
Banahan III B¹, Nunna S¹, Shah R¹, Harwick SP², Clark JP²,¹University of Mississippi, University, MS, USA, ²Mississippi Division of Medicaid, Jackson, MS, USA
- PHS169 I11 pgA275 **QUALITY AND IMPLEMENTATION BARRIERS OF PREVENTION OF MOTHER TO CHILD TRANSMISSION OF HIV PROGRAM IN ETHIOPIA: A CROSS SECTIONAL STUDY**
Legesse B, Karolinska Institutet, Stockholm, Sweden
- PHS170 I12 pgA276 **QUALITY OF CARE FOR CHILDHOOD ATTENTION DEFICIT/HYPERACTIVITY DISORDER: A RETROSPECTIVE ANALYSIS OF MISSISSIPPI MEDICAID PROGRAM**
Suryavanshi M¹, Banahan III B², Hardwick SP³, Clark JP³,¹University of Mississippi, Oxford, MS, USA, ²University of Mississippi, University, MS, USA, ³Mississippi Division of Medicaid, Jackson, MS, USA
- PHS171 I13 pgA276 **DISEASE-SPECIFIC DISTRIBUTION OF HEALTH CARE QUALITY MEASURES IN THE UNITED STATES**
Nicholson GL, Halbert RJ, ICON plc, El Segundo, CA, USA
- PHS172 I14 pgA276 **MEASURING LOW-VALUE HEALTH SERVICES USING HEALTH INSURANCE CLAIMS DATA**
Tong J¹, Kralewski J¹, Dowd B¹, Carlin C²,¹University of Minnesota, Minneapolis, MN, USA, ²Medica Research Institute, Minneapolis, MN, USA
- PHS173 J1 pgA276 **INITIATION AND EVALUATION OF CLINICAL PHARMACY SERVICES TO SURGICAL WARD IN A SOUTH INDIAN TERTIARY CARE TEACHING HOSPITAL**
Adepu R, Sharon S, JSS University, Mysore, India
- PHS174 J2 pgA276 **OUTPATIENT FOLLOW-UP VISITS AFTER HOSPITAL DISCHARGE FOR MENTAL ILLNESS AND IMPLICATIONS FOR RE-ADMISSIONS**
Lin J¹, Muser E², Munsell M¹, Menzin J¹,¹Boston Health Economics, Inc., Waltham, MA, USA, ²Janssen Scientific Affairs, LLC, Titusville, NJ, USA
- PHS175 J3 pgA277 **DECREASING EBM ORDER SET REVIEW AND APPROVAL CYCLE TIME**
Castree KL, Cinciripini CL, Hospital Sisters Health System, Belleville, IL, USA
- PHS176 J4 pgA277 **PATIENT VALUATION OF DIFFERENT APPROACHES TO MENTAL HEALTH AND SUBSTANCE USE DISORDER TREATMENT**
Epstein AJ¹, Barry CL², Fiellin DA³, Busch SH³,¹University of Pennsylvania, Philadelphia, PA, USA, ²Johns Hopkins University, Baltimore, MD, USA, ³Yale University, New Haven, CT, USA
- PHS178 J5 pgA277 **HOSPITAL COST AND QUALITY TRENDS BEFORE AND AFTER ACO ADOPTION**
Cutler E¹, Henke RE¹, **Marder WD**¹, Karaca Z², Wong H²,¹Truven Health Analytics, Cambridge, MA, USA, ²Agency for Healthcare Research and Quality, Rockville, MD, USA
- PHS179 J6 pgA277 **READMISSION PATTERNS IN MEDICARE BENEFICIARIES HOSPITALIZED FOR HEART FAILURE**
Kilgore M¹, Sharma P¹, Patel H², Maya J², Kielhorn A²,¹University of Alabama at Birmingham, Birmingham, AL, USA, ²Amgen, Thousand Oaks, CA, USA

DISEASE- SPECIFIC STUDIES

NEUROLOGICAL DISORDERS - Clinical Outcomes Studies

- PND1 J7 pgA277 **EFFECTIVENESS OF PHARMACOTHERAPY IN CHILDREN WITH SYMPTOMATIC EPILEPSY**
Bhardwaj A¹, Bansal D¹, Azad C²,¹National Institute of Pharmaceutical Education and Research, Mohali, India, ²Government Medical College and Hospital, Chandigarh, India
- PND2 J8 pgA277 **COMPARATIVE STUDY OF THE INFLUENCE OF BIAPENEM AND MEROPENEM ON VALPROIC ACID BLOOD CONCENTRATION**
Tang L, Suzhou Municipal Hospital, Suzhou, China
- PND3 J9 pgA278 **SYSTEMATIC LITERATURE REVIEW OF TREATMENTS OF CHRONIC CLUSTER HEADACHE**
Medic G¹, Thavaneswaran S², Papadimitropoulou K¹, Stauble F², Karabis A¹,¹MAPI Group, Houten, The Netherlands, ²Medtronic International, Tolochenaz, Switzerland
- PND4 J10 pgA278 **RISK OF CARDIOVASCULAR EVENTS ASSOCIATED WITH NECESSARY INTERVENTIONS FOR PARKINSON DISEASE**
Crispo J¹, Willis AW², Fortin Y¹, Emons MF³, Bjerre LM¹, Kohen DE¹, Perez Lloret S⁴, Mattison DR⁵, Krewski D¹,¹University of Ottawa, Ottawa, ON, Canada, ²University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA, ³Cerner Corporation, Culver City, CA, USA, ⁴Catholic University, Buenos Aires, Argentina, ⁵Risk Sciences International, Ottawa, ON, Canada
- PND5 J11 pgA278 **SPECIFICITY AND SENSITIVITY OF AQUAPORIN 4 ANTIBODY DETECTION TESTS IN PATIENTS WITH**

NEUROMYELITIS OPTICA: A META-ANALYSIS

Ruiz R¹, **Castañeda-Cardona C**¹, Ruiz-Patiño A², Rosselli D¹,¹ Pontificia Universidad Javeriana, Bogota, Colombia, ²Hospital Universitario San Ignacio, Bogotá, Colombia

- PND6 J12** *pgA278* **CLASSIFICATION OF NON-HIV LIPODYSTROPHY IN THE US USING ELECTRONIC MEDICAL RECORD (EMR) DATA AND PHYSICIAN NOTES**
Oral E¹, Lang K², Campion N², Dhankhar P³, Joseph C⁴, Garg A⁵,¹University of Michigan, Ann Arbor, MI, USA, ²Quintiles, Cambridge, MA, USA, ³AstraZeneca, Fort Washington, PA, USA, ⁴Quintiles, Rockville, MD, USA, ⁵University of Texas Southwestern Medical Center, Dallas, TX, USA
- PND7 J13** *pgA278* **TOTAL MIGRAINE FREEDOM FOR BREATH POWERED INTRANASAL DELIVERY OF 22 MG SUMATRIPTAN POWDER (AVP-825) VERSUS 100 MG ORAL SUMATRIPTAN FROM THE COMPASS STUDY OF ACUTE TREATMENT OF MIGRAINE**
Halker R¹, Tepper S², Siegert S³, **Wallick C**³,¹Mayo Clinic Phoenix, Scottsdale, AZ, USA, ²Cleveland Clinic, Cleveland, OH, USA, ³Avanir Pharmaceuticals, Inc., Aliso Viejo, CA, USA
- PND8 J14** *pgA279* **PATIENT SELF-ASSESSMENTS IN ADVANCED PARKINSON'S DISEASE WITHIN UPDRS AND "OFF" TIME SUBGROUPS: COMPARISON OF IPX066 WITH IMMEDIATE-RELEASE CARBIDOPA-LEVODOPA**
Rubens R, Rustay NR, Khanna S, Kell S, Gupta S, Impax Laboratories, Inc., Hayward, CA, USA
- PND9 K1** *pgA279* **THE EFFICACY OF MELATONIN FOR PRIMARY INSOMNIA: A SYSTEMATIC REVIEW AND META-ANALYSIS**
Suh HS, Lee YJ, Je N, Pusan National University, Busan, South Korea
- PND10 K2** *pgA279* **COMPARISON OF CLINICAL EFFECTIVENESS OF TREATMENTS FOR PSEUDOBULBAR AFFECT (PBA) – RESULTS FROM A SYSTEMATIC REVIEW**
Baculea S¹, Barcena L¹, Singh M¹, Mealing S¹, Yonan C²,¹ICON Clinical Research (UK) Ltd., Oxford, UK, ²Avanir Pharmaceuticals, Inc., Aliso Viejo, CA, USA
- PND11 K3** *pgA279* **TERIFLUNOMIDE SHOWS CONSISTENT CLINICAL EFFICACY ON SEVERE RELAPSES ACROSS TEMSO AND TOWER: 2 PHASE 3 TRIALS**
Leist TP¹, Stangel M², Macdonell R³, Mäurer M⁴, Thangavelu K⁵, Truffinet P⁶, Bozzi S⁷, Dive-Pouletty C⁶, Freedman MS⁸,¹Thomas Jefferson University Hospital, Philadelphia, PA, USA, ²Medizinische Hochschule Hannover, Hannover, Germany, ³Austin Health, Heidelberg, Australia, ⁴Caritas Krankenhaus Bad Mergentheim, Bad Mergentheim, Germany, ⁵Genzyme, a Sanofi company, Cambridge, MA, USA, ⁶Genzyme, a Sanofi company, Chilly-Mazarin, France, ⁷Sanofi, Chilly-Mazarin, France, ⁸University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada
- PND12 K4** *pgA279* **ESTIMATION OF TIME TO REACH RRMS EDSS HEALTH STATES ≥ 7.0 OR SPMS FOR DELAYED-RELEASE DIMETHYL FUMARATE**
Walker A¹, Berling M², Malmenäs M², Brodtkorb T³, Alvarez-Reyes M⁴,¹Heron Commercialization, London, UK, ²Heron Commercialization, Stockholm, Sweden, ³RTI Health Solutions, Ljungskile, Sweden, ⁴Biogen Idec International GmbH, Zug, Switzerland
- PND13 K5** *pgA279* **"NUMBER NEEDED TO TREAT" ANALYSIS TO ASSESS THE COMPARATIVE OUTCOMES FROM TERIFLUNOMIDE AND DIMETHYL FUMARATE STUDIES IN RELAPSING MULTIPLE SCLEROSIS**
Leist TP¹, Montalban X², Miller AE³, Dive-Pouletty C⁴, Freedman MS⁵,¹Thomas Jefferson University Hospital, Philadelphia, PA, USA, ²Vall d'Hebron University Hospital, Barcelona, Spain, ³Icahn School of Medicine at Mount Sinai, New York, NY, USA, ⁴Genzyme, a Sanofi company, Chilly-Mazarin, France, ⁵University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada
- PND14 K6** *pgA280* **INTERFERON-Â THERAPIES FOR THE TREATMENT OF MULTIPLE SCLEROSIS IN BRAZIL: A SYSTEMATIC REVIEW WITH META-ANALYSIS**
Junqueira M¹, Clark OA², Wong S³, Fujii RK¹,¹Merck Serono, São Paulo, Brazil, ²Evidências - Kantar Health, Campinas, Brazil, ³EMD Serono, Inc., Billerica, MA, USA
- PND15 K7** *pgA280* **BAYESIAN MIXED TREATMENT COMPARISON OF EARLY TREATMENT FOR PARKINSON DISEASE: AN INDIRECT COMPARISON**
Marquez M¹, Diaz JP², Ibarra A¹, Pizarro M³, Cervantes A⁴, Rodríguez M⁴, Soto H¹,¹Universidad Autonoma Metropolitana, México D.F., Mexico, ²Universidad Nacional Autonoma de Mexico, México D.F., Mexico, ³Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico, ⁴Instituto Nacional de Neurología y Neurocirugía, México D.F., Mexico

NEUROLOGICAL DISORDERS - Cost Studies

- PND17 K8** *pgA280* **ALEMTUZUMAB BUDGET IMPACT ANALYSIS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE US**
Celestin C¹, Wandstrat T¹, Coleman Cl²,¹Genzyme, a Sanofi company, Cambridge, MA, USA, ²University of Connecticut/Hartford Hospital Evidence-Based Practice Center, Hartford, CT, USA
- PND18 K9** *pgA280* **BUDGET IMPACT OF ADDING PEGINTERFERON BETA-1A TO THE FORMULARY FOR THE TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS**
Mauskopf JA¹, Graham J², Fay-Azhar M³, Kinter E³,¹RTI Health Solutions, Research Triangle Park, NC, USA, ²RTI-Health Solutions, Research Triangle Park, NC, USA, ³Biogen Idec, Weston, MA, USA

- PND19 K10** *pgA281* **HOSPITAL BUDGET IMPACT OF SUGAMMADEX (BRIDION®) FOR REVERSAL OF NEUROMUSCULAR BLOCKADE**
Insinga R, Maiese EM, Devine S, Merck & Co., Inc., Kenilworth, NJ, USA
- PND20 K11** *pgA281* **BUDGET IMPACT OF CHOSING REBIF® AS THE INTERFERON OF CHOICE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE BRAZILIN PUBLIC HEALTHCARE SYSTEM**
Fujii RK¹, Wong S², Junqueira M¹,¹Merck Serono, São Paulo, Brazil, ²EMD Serono, Inc., Billerica, MA, USA
- PND21 K12** *pgA281* **CALCULATING THE COSTS OF ADVERSE DRUG REACTIONS FROM POST-MARKETING DATA: IMPLICATIONS FOR OUTCOMES RESEARCH**
Hoffman KB, Dimbil M, AdverseEvents, Inc., Santa Rosa, CA, USA
- PND22 K13** *pgA281* **AN ASSESSMENT OF FACTORS ASSOCIATED WITH HIGH COSTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS (MS) RECEIVING DISEASE-MODIFYING DRUG (DMD) THERAPY**
Locklear JC¹, Frean M², Phillips AL¹, Menzin J²,¹EMD Serono, Inc., Rockland, MA, USA, ²Boston Health Economics, Inc., Waltham, MA, USA
- PND23 K14** *pgA281* **A COMPARISON OF HEALTHCARE RESOURCE UTILIZATION AND ASSOCIATED COSTS IN ADULTS WITH GENERALIZED CONVULSIVE SEIZURES (GCS)**
 Li X¹, Barghout V², Wang Z³,¹Eisai, Inc., Woodcliff Lake, NJ, USA, ²VEB Healthcare LLC., Morristown, NJ, USA, ³Eisai Inc., Woodcliff Lake, NJ, USA
- PND24 K15** *pgA282* **PRICE ANALYSIS OF MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPIES MARKETED IN THE US**
Bin Sawad A¹, Seoane-Vazquez E¹, Rodriguez-Monguio R²,¹MCPHS University, Boston, MA, USA, ²School of Public Health and Health Sciences, UMASS, Amherst, MA, USA
- PND25 K16** *pgA282* **THE ECONOMIC BURDEN OF SPINAL MUSCULAR ATROPHY**
Armstrong EP¹, Malone DC², Yeh W³, Dahl GJ⁴, Lee R⁵, Sicignano N⁶,¹Strategic Therapeutics. LLC, Oro Valley, AZ, USA, ²University of Arizona, Tucson, AZ, USA, ³Biogen Idec, Cambridge, MA, USA, ⁴Naval Medical Center Portsmouth, Portsmouth, VA, USA, ⁵Naval Medical Research Unit Dayton, Dayton, OH, USA, ⁶Health ResearchTx, Trevoise, PA, USA
- PND27 K17** *pgA282* **OUT OF POCKET COST FOR PEDIATRIC EPILEPSY MANAGEMENT: RESULTS FROM MALAYSIAN POPULATION**
Kashyap M, Bahari B, AIMST University, Semeling, Malaysia
- PND28 K18** *pgA282* **ANALYSIS OF MEDICAL COSTS OF RRMS RELAPSES**
Nakamura Y, Milliman, Tokyo, Japan
- PND29 L1** *pgA282* **A RETROSPECTIVE ANALYSIS OF THE ECONOMIC BURDEN AMONG PATIENTS DIAGNOSED WITH CHRONIC MIGRAINE USING THE VETERANS HEALTH ADMINISTRATION MEDICAL DATA**
 Mao X¹, Shrestha S², Baser O³, Wang L²,¹University of Texas at Dallas and STATinMED Research, Plano, TX, USA, ²STATinMED Research, Plano, TX, USA, ³STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA
- PND30 L2** *pgA283* **HEALTH CARE RESOURCE UTILIZATIONS AND COSTS AMONG MIGRAINE PATIENTS IN THE U.S. MEDICAID POPULATION**
 Huang A¹, Shrestha S¹, Baser O², Yuce H³, Wang L¹,¹STATinMED Research, Plano, TX, USA, ²STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA, ³City University of New York & STATinMED Research, New York, NY, USA
- PND31 L3** *pgA283* **COST-EFFECTIVENESS ANALYSIS OF IPX066 IN ADVANCED PARKINSON'S DISEASE**
Arnold RJ¹, Frasco MA¹, Layton A¹, Rustay NR², Chen S²,¹Quorum Consulting, San Francisco, CA, USA, ²Impax Laboratories, Inc., Hayward, CA, USA
- PND32 L4** *pgA283* **COST EFFECTIVENESS OF LEVODOPA/CARBIDOPA INTESTINAL GEL IN IRELAND**
Baj R, Egan KM, McCarthy J, AbbVie Ltd., Dublin, Ireland
- PND33 L5** *pgA283* **THE COST-EFFECTIVENESS OF DISEASE MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS**
 Bozkaya D¹, Livingston TP², Migliaccio-Walle K¹, Mehta S², Odom T²,¹Xcenda, Palm Harbor, FL, USA, ²Biogen Idec, Weston, MA, USA
- PND34 L6** *pgA283* **"COST EFFECTIVENESS ANALYSIS OF MOST COMMONLY PRESCRIBED DRUGS IN MIGRAINE"**
Upreti AR, Kathmandu University, kathmandu, Nepal
- PND35 L7** *pgA283* **COST EFFECTIVENESS OF EARLY TREATMENT OF PARKINSON'S DISEASE IN MEXICO**
Marquez M¹, Diaz JP², Pizarro M³, Ibarra A¹, Cervantes A⁴, Rodríguez M⁴, Soto H¹,¹Universidad Autonoma Metropolitana, México D.F., Mexico, ²Universidad Nacional Autonoma de Mexico, México D.F., Mexico, ³Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico, ⁴Instituto Nacional de Neurología y Neurocirugía, México D.F., Mexico
- PND36 L8** *pgA284* **THE COST-EFFECTIVENESS OF LISDEXAMFETAMINE DIMESYLATE FOR THE TREATMENT OF BINGE EATING DISORDER**
 Ágh T¹, Pawaskar M², Voko Z¹, Nagy B¹, Lachaine J³,¹Syreon Research Institute, Budapest, Hungary, ²Shire

- Development LLC, wayne, PA, USA, ³University of Montreal, Montreal, QC, Canada
- PND37 L9** *pgA284* **THE IMPACT OF NEUTRALIZING ANTIBODY TESTING ON THE COST-EFFECTIVENESS OF INJECTABLE DISEASE MODIFYING TREATMENTS FOR RELAPSING REMITTING MULTIPLE SCLEROSIS**
Andreykiv M¹, Plich A¹, **Prüfert A**², Heemstra L², Van Engen A^{2,1}, Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands, ²Quintiles Consulting, Hoofddorp, The Netherlands
- PND38 L10** *pgA284* **TRACKING HEALTHCARE UTILIZATION (COST) IN PSEUDOBULBAR AFFECT PATIENTS TREATED WITH NUDEXTA**
Palmgren M¹, Cyhaniuk A², Yonan C³, **Potente E**³, ¹Int'Ovation, Marietta, GA, USA, ²AC Analytical Solutions, Barrington, IL, USA, ³Avanir Pharmaceuticals, Inc., Aliso Viejo, CA, USA
- PND39 L11** *pgA284* **HEALTH CARE RESOURCE UTILIZATION BEFORE AND AFTER NATALIZUMAB INITIATION AMONG MULTIPLE SCLEROSIS PATIENTS IN GERMANY**
Watson C¹, Prosser C², Braun S², Landsman-Blumberg P³, Naoshy S¹, ¹Biogen Idec, Cambridge, MA, USA, ²Xcenda GmbH, Hannover, Germany, ³Xcenda LLC, Palm Harbor, FL, USA
- PND40 L12** *pgA284* **SKELETAL MUSCLE ACTIVITY AND RESOURCE TOOL FOR SPORADIC INCLUSION BODY MYOSITIS (SMART-SIBM): CHARACTERIZATION OF RESOURCE UTILIZATION AND FINANCIAL BURDEN EXPERIENCED BY SIBM PATIENTS**
Barghout V¹, DeMuro C², Price M², Lewis S², Tseng B³, ¹VEB Healthcare LLC., Morristown, NJ, USA, ²RTI Health Solutions, Research Triangle Park, NC, USA, ³Novartis Pharmaceuticals, Cambridge, MA, USA

NEUROLOGICAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

- PND41 L13** *pgA285* **DESCRIPTION OF PROPHYLACTIC DRUG UTILIZATION PATTERNS IN MIGRAINE PATIENTS**
Shei A¹, Woolley JM², **Desai PR**², Enloe CJ¹, Kirson NY¹, Birnbaum HG¹, Corey-Lisle PK³, Sapra S^{2,1}, Analysis Group, Inc., Boston, MA, USA, ²Amgen Inc., Thousand Oaks, CA, USA, ³EMD Serono, Inc., Rockland, MA, USA
- PND42 L14** *pgA285* **A REVIEW OF METHODOLOGIES USED TO ASSESS ADHERENCE TO DISEASE MODIFYING THERAPIES AMONG PATIENTS WITH MULTIPLE SCLEROSIS**
Thach A, Chimah C, Makhinova T, Brown C, The University of Texas at Austin, Austin, TX, USA
- PND43 L15** *pgA285* **ADHERENCE AND PERSISTENCE TO ANTI-EPILEPTIC DRUGS AMONG U.S. VETERANS DIAGNOSED WITH EPILEPSY**
Velez FF¹, Baser O², Xie L³, ¹Sunovion Pharmaceuticals Inc, Marlborough, MA, USA, ²STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA, ³STATinMED Research, Ann Arbor, MI, USA
- PND44 L16** *pgA285* **MEASURING ADHERENCE AND OUTCOME IN TREATMENT OF MULTIPLE SCLEROSIS IN THE GEISINGER CLINIC**
Graham JH¹, **Hao J**¹, Pitcavage JM¹, Hoegerl CR², Jones J³, Taylor SR¹, Ryman AM⁴, ¹Geisinger Health System, Danville, PA, USA, ²Liberty University, Lynchburg, VA, USA, ³Sutter Health, Research, Development & Dissemination, Walnut Creek, CA, USA, ⁴University of Pittsburgh, Pittsburgh, PA, USA
- PND45 L17** *pgA285* **WHAT ARE PEOPLE WILLING TO PAY FOR WHOLE GENOME SEQUENCING INFORMATION?**
Marshall DA¹, Gonzalez JM², Johnson FR³, Pugh A², MacDonald KV⁴, Douglas MP⁵, Phillips KA⁵, ¹Alberta Bone and Joint Health Institute, Calgary, AB, Canada, ²RTI Health Solutions, Research Triangle Park, NC, USA, ³Duke University, Durham, NC, USA, ⁴University of Calgary, Calgary, AB, Canada, ⁵University of California – San Francisco, San Francisco, CA, USA
- PND46 L18** *pgA286* **ESTIMATING THE VALUE OF WHOLE EXOME SEQUENCING FOR PARENTS OF CHILDREN WITH RARE GENETIC DISEASES**
Marshall DA¹, MacDonald KV², Lopatina E², Mackenzie A³, Hartley T³, Boycott K³, ¹Alberta Bone and Joint Health Institute, Calgary, AB, Canada, ²University of Calgary, Calgary, AB, Canada, ³Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, Canada
- PND47 M1** *pgA286* **PATIENT-REPORTED OUTCOME MEASURES FOR MULTIPLE SCLEROSIS PHASE IV CLINICAL TRIALS: A SYSTEMATIC REVIEW**
Ting J¹, Zhong L², Petrillo J², Niu C³, Lee A², Sarda S², ¹University of California, San Francisco, San Francisco, CA, USA, ²Biogen Idec, Cambridge, MA, USA, ³University of Southern California, Los Angeles, CA, USA
- PND48 M2** *pgA286* **A NOVEL MEASURE TO ASSESS SELF-REPORTED PHYSICAL FUNCTIONING IN PATIENTS WITH SPORADIC INCLUSION BODY MYOSITIS (SIBM)**
DeMuro C¹, Lewis S¹, Pax Lowes L², Alfano L², Tseng B³, Gnanasakthy A¹, ¹RTI Health Solutions, Research Triangle Park, NC, USA, ²Nationwide Children's Hospital, Columbus, OH, USA, ³Novartis Pharmaceuticals, Cambridge, MA, USA
- PND49 M3** *pgA286* **UNDERSTANDING THE SUITABILITY OF CYSTIC FIBROSIS-SPECIFIC CLINICAL OUTCOME ASSESSMENTS FOR CLINICAL TRIALS AND TO SUPPORT MEDICAL PRODUCT LABELING**
Willgoss TG¹, Trigg A¹, Meysner S¹, Kitchen H¹, Humphrey L¹, Blankenburg M², ¹Abacus International, Manchester, UK, ²Bayer HealthCare Pharmaceuticals, Berlin, Germany
- PND50 M4** *pgA286* **THE PARKINSON'S DISEASE QUESTIONNAIRE (PDQ-39) - EVALUATING THE PSYCHOMETRIC PROPERTIES OF AN ELECTRONIC VERSION**
Morley D¹, Jenkinson C¹, Dummett S¹, Kelly L¹, **Churchman DR**², Dawson J¹, ¹University of Oxford, Oxford,

UK, ²Isis Innovation Ltd, Oxford, UK

- PND51 M5** *pgA286* **SEX DIFFERENCES IN OVER-THE-COUNTER SLEEP AID USE IN OLDER ADULTS**
Gross HJ¹, O'Neill G², Toscani M³, **Chapnick J**^{4,1}, Kantar Health, Princeton, NJ, USA, ²Gerontological Society of America, Washington, DC, USA, ³Ernest Mario School of Pharmacy, Piscataway, NJ, USA, ⁴Kantar Health, Horsham, PA, USA
- PND52 M6** *pgA287* **BURDEN OF ILLNESS FOR PATIENTS WITH FAMILIAL AMYLOIDOTIC POLYNEUROPATHY (FAP) BEGINS EARLY AND INCREASES WITH DISEASE PROGRESSION**
Denoncourt RN¹, Adams D², Coelho T³, Bettencourt BR¹, Plaisted A¹, Amitay O¹, Falzone R¹, Harrop J¹, White L¹, De Frutos R¹, Cehelsky J¹, Nochur S¹, Vaishnav AK¹, Gollob J¹, Alnylam Pharmaceuticals, Cambridge, MA, USA, ²Centre Paris-Sud, APHP, Hopital de Bicetre, INSERM U788, Service de Neurologie, and Centre de Reference des Neuropathies Amyloides Familiales, Le Kremlin-Bicetre, France, ³Unidade Clinica de Paramiloidose, Hospital de Santo Antonio, Porto, Portugal
- PND53 M7** *pgA287* **A NOVEL CONCEPTUAL MODEL OF CYSTIC FIBROSIS BASED ON QUALITATIVE PATIENT RESEARCH**
Willgoss TG¹, Trigg A¹, Meysner S¹, Kitchen H¹, Humphrey L¹, Blankenburg M^{2,1}, Abacus International, Manchester, UK, ²Bayer HealthCare Pharmaceuticals, Berlin, Germany
- PND54 M8** *pgA287* **AWARENESS AND KNOWLEDGE OF FOLIC ACID INTAKE FOR THE PREVENTION OF NEURAL TUBE DEFECTS AMONG WOMEN OF CHILDBEARING AGE**
Alwhaibi M, Dwibedi N, Garg R, West Virginia University, Morgantown, WV, USA
- PND55 M9** *pgA287* **QUALITY-OF-LIFE PREDICTORS OF TREATMENT CONTINUATION ON ESLICARBAZEPINE ACETATE MONOTHERAPY AMONG SUBJECTS WITH REFRACTORY PARTIAL-ONSET SEIZURES**
Bond TC¹, **Velez FF**², Cramer JA³, Anastassopoulos KP¹, Wang X¹, Sousa R⁴, Rocha F⁴, Blum D^{2,1}, Covance Market Access, Gaithersburg, MD, USA, ²Sunovion Pharmaceuticals Inc., Marlborough, MA, USA, ³Yale University, Houston, TX, USA, ⁴BIAL, S. Mamede do Coronado, Portugal
- PND56 M10** *pgA287* **TREATMENT SATISFACTION AMONG PATIENTS TREATED WITH MONOTHERAPY AND ADJUNCTIVE ANTI-EPILEPTIC DRUG THERAPIES**
Lee LK¹, **Velez FF**², Pomerantz D³, DiBonaventura MD^{4,1}, Kantar Health, Foster City, CA, USA, ²Sunovion Pharmaceuticals Inc, Marlborough, MA, USA, ³Kantar Health, Horsham, PA, USA, ⁴Kantar Health, New York, NY, USA
- PND57 M11** *pgA287* **QUALITY OF LIFE IN NEUROMYELITIS OPTICA: A SYSTEMATIC REVIEW**
Likhar N, **Dang A**, MarksMan Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India
- PND58 M12** *pgA288* **QUALITY OF LIFE OF PATIENTS WITH PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS**
Chekani E, Bali V, Aparasu RR, University of Houston, Houston, TX, USA
- PND59 M13** *pgA288* **IMPACT OF YOUNG-ONSET PARKINSON'S DISEASE ON QUALITY OF LIFE – A LITERATURE REVIEW**
Sosnowski L¹, Kamal KM¹, Pawar G^{2,1}, Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA, USA, ²West Virginia University School of Medicine, Morgantown, WV, USA
- PND60 M14** *pgA288* **QUALITY OF LIFE IN ADULT PATIENTS WITH CYSTIC FIBROSIS – A SYSTEMATIC REVIEW**
Parekh MH¹, Ipatova A¹, Dashputre AA¹, Kamal KM^{2,1}, Mylan School of Pharmacy Duquesne University, Pittsburgh, PA, USA, ²Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA, USA
- PND61 M15** *pgA288* **DOES HEALTH-RELATED QUALITY OF LIFE EVALUATION IN MULTIPLE SCLEROSIS (MS) MATTER? A REVIEW OF LABELS OF MS PRODUCTS APPROVED BY THE FDA AND EMA**
Acquadro C¹, **Perret C**¹, Arnould B^{2,1}, Mapi Research Trust, Lyon, France, ²Mapi, Lyon, France
- PND62 M16** *pgA288* **WILLINGNESS-TO-PAY FOR NEWBORN GENETIC TESTING FOR SPINAL MUSCULAR ATROPHY**
Lin P¹, Shi J¹, Yeh W², Neumann PJ^{3,1}, Tufts Medical Center, Boston, MA, USA, ²Biogen Idec, Cambridge, MA, USA, ³Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
- PND63 M17** *pgA289* **THE EVALUATION OF WORK PRODUCTIVITY IN RELAPSING-REMITTING (RRMS) AND SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) PATIENTS IN EUROPE**
Pike J¹, Naoshy S², Watson C², Jones E^{1,1}, Adelphi Real World, Manchester, UK, ²Biogen Idec, Cambridge, MA, USA

NEUROLOGICAL DISORDERS - Health Care Use & Policy Studies

- PND65 M18** *pgA289* **SURVEY OF PHYSICIANS REGARDING APPLICATION AND UTILITY OF PHARMACOGENOMICS RESULTS IN THE MANAGEMENT OF CHRONIC MEDICAL CONDITIONS**
Delgado A¹, Villarreal SM¹, Gurnani P², Rosenblatt K², Koeller JM^{1,1}, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA, ²CompanionDx, Houston, TX, USA
- PND66 N1** *pgA289* **TWENTY YEARS OF TRIPTANS IN THE UNITED STATES MEDICAID PROGRAMS: UTILIZATION AND REIMBURSEMENT TRENDS FROM 1993-2013**
Xia Y, Kelton CM, Wigle PR, Guo JJ, University of Cincinnati, Cincinnati, OH, USA
- PND67 N2** *pgA289* **SPECIALTY TIER COST SHARING AND USE OF DISEASE MODIFYING THERAPIES AMONG MEDICARE**

BENEFICIARIES WITH MULTIPLE SCLEROSIS

Doshi JA¹, Li P¹, Yu X¹, Dahodwala NA¹, Chahin S²,¹University of Pennsylvania, Philadelphia, PA, USA, ²University of Pennsylvania Health System, Philadelphia, PA, USA

- PND68 N3** *pgA289* **TRENDS ASSOCIATED WITH IMPLEMENTING AND LIFTING A STEP THERAPY POLICY FOR PREGABALIN IN THE HUMANA MEDICARE POPULATION: AN INTERRUPTED TIME SERIES ANALYSIS**
Null KD¹, Moll K¹, Cappelleri JC², Sadosky A³, Parsons B³, Pasquale MK¹,¹Comprehensive Health Insights, Louisville, KY, USA, ²Pfizer Inc, Groton, CT, USA, ³Pfizer Inc, New York, NY, USA
- PND69 N4** *pgA289* **HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH RESCUE MEDICATION USE IN ADULT PATIENTS WITH SEIZURE CLUSTERS: A RETROSPECTIVE CHART REVIEW**
Vazquez B¹, Sidovar M², Squillacote D², Wu E³, Macaulay D³, Sorg R³, Guo A²,¹Comprehensive Epilepsy Center, New York, NY, USA, ²Acorda Therapeutics, Inc., Ardsley, NY, USA, ³Analysis Group, Inc., New York, NY, USA
- PND70 N5** *pgA290* **IMPACT OF WALKING IMPAIRMENT ON HEALTHCARE RESOURCE UTILISATION IN MULTIPLE SCLEROSIS PATIENTS**
Liu Y¹, Pike J², Lee A¹, Hibbert C³, Hoskin B⁴,¹Biogen Idec, Cambridge, MA, USA, ²Adelphi Real World, Manchester, UK, ³Biogen Idec International, Zug, Switzerland, ⁴Adelphi Real World, Macclesfield, MA, USA
- PND71 N6** *pgA290* **HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH DALFAMPRIDINE EXTENDED RELEASE IN MULTIPLE SCLEROSIS: A RETROSPECTIVE CLAIMS DATABASE ANALYSIS**
Krieger S¹, Palli SR², Grabner M³, Elder J⁴, Aupperle P⁴, Guo A⁴,¹Icahn School of Medicine at Mount Sinai, New York, NY, USA, ²CTI Clinical Trial & Consulting, Cincinnati, OH, USA, ³HealthCore Inc., Wilmington, DE, USA, ⁴Acorda Therapeutics, Inc., Ardsley, NY, USA
- PND72 N7** *pgA290* **PARKINSON'S DISEASE AND CAREGIVER BURDEN: RESULTS FROM THE NATIONAL ALLIANCE OF CAREGIVING SURVEY**
Bhattacharjee S¹, Metzger A², Tworek C², Wei W³, Pan X⁴, Sambamoorthi U²,¹The University of Arizona, Tucson, AZ, USA, ²West Virginia University, Morgantown, WV, USA, ³Sanofi US LLC, Bridgewater, NJ, USA, ⁴Evidera LLC, Lexington, MA, USA
- PND73 N8** *pgA290* **METHODOLOGICAL ISSUES IN CLASSIFYING ADJUNCT ANTI EPILEPTIC DRUG (AED) TREATMENT IN CLAIMS DATA: ANALYSIS OF THE EFFECT OF THE MINIMUM AED CO-ADMINISTRATION PERIOD**
Brook RA¹, Smeeding JE², Young JW³, Velez FF⁴,¹The JeSTARx Group, Newfoundland, NJ, USA, ²The JeSTARx Group, Dallas, TX, USA, ³HCMS Group, Cheyenne, WY, USA, ⁴Sunovion Pharmaceuticals Inc, Marlborough, MA, USA
- PND74 N9** *pgA290* **ORAL DISEASE MODIFYING THERAPY FOR MULTIPLE SCLEROSIS; IS THIS THE NEW NORMAL?**
Johnson BH, Truven Health Analytics, Cambridge, MA, USA
- PND75 N10** *pgA291* **SLEEP MEDICATION USERS AND THEIR CHARACTERISTICS**
Anupindi VR, Shah D, Vaidya V, University of Toledo, Toledo, OH, USA
- PND76 N11** *pgA291* **A DESCRIPTIVE ANALYSIS OF TIME TO FIRST TREATMENT WITH DISEASE-MODIFYING DRUGS (DMDS) IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE SCLEROSIS (MS)**
Phillips AL¹, Edwards NC², Sutherland S³,¹EMD Serono, Inc., Rockland, MA, USA, ²Health Services Consulting Corporation, Boxborough, MA, USA, ³Boston Health Economics, Inc., Waltham, MA, USA
- PND77 N12** *pgA291* **TREATMENT PATTERNS OF MONOTHERAPY VERSUS COMBINATION ANTIEPILEPTIC DRUG THERAPY IN PATIENTS WITH EPILEPSY**
Gupte KP, Rascati KL, Wilson JP, The University of Texas at Austin, College of Pharmacy, Austin, TX, USA

SYSTEMIC DISORDERS/CONDITIONS - Clinical Outcomes Studies

- PSY1 N13** *pgA291* **RISK OF GLUCOCORTICOID-RELATED ADVERSE EVENTS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: FINDINGS FROM A 12-YEAR LONGITUDINAL FOLLOW-UP STUDY IN TAIWAN**
Chen H¹, Shen L¹, Hsu P¹, Shen C¹, Hall SA², Hsiao F¹,¹National Taiwan University, Taipei, Taiwan, ²Biogen Idec, Cambridge, MA, USA
- PSY2 N14** *pgA291* **A REVIEW OF INTRAOPERATIVE INTERVENTIONS TO PREVENT STAPLE LINE LEAKS AND BLEEDS DURING BARIATRIC SURGICAL PROCEDURES**
Ghosh SK¹, Roy S², Chekan E³, Fegelman E¹,¹Johnson & Johnson (Ethicon), Cincinnati, OH, USA, ²Johnson & Johnson (Ethicon), Somerville, NJ, USA, ³Johnson & Johnson (Ethicon), Cincinnati, OH, USA
- PSY3 N15** *pgA292* **RISK OF CARDIOVASCULAR, GASTROINTESTINAL, AND RENAL ADVERSE EVENTS ASSOCIATED WITH DICLOFENAC IMMEDIATE AND EXTENDED RELEASE DRUG PRODUCTS: AN OBSERVATIONAL STUDY USING US CLAIMS DATA**
Mladsji DM¹, Goyal RK¹, Cryer B², Hopkins WE³, Brater CD⁴, Korsnes JS¹, Candrilli S¹, Castellsague J⁵, Varas-Lorenzo C⁵,¹RTI Health Solutions, Research Triangle Park, NC, USA, ²University of Texas Southwestern and VA North Texas Health Care System, Dallas, TX, USA, ³University of Vermont College of Medicine, South Burlington, VT, USA, ⁴Walther Cancer Foundation and Regenstrief Foundation, Indianapolis, IN, USA, ⁵RTI Health Solutions, Barcelona, Spain
- PSY4 N16** *pgA292* **LESSONS LEARNED FROM THE PILOT INTRODUCTION OF PEGINESATIDE, A THIRD GENERATION ERYTHROPOIESIS STIMULATING AGENT**

Bennett C, University of South Carolina College of Pharmacy, Columbia, SC, USA

PSY5 N17 pgA292 THE VALIDITY OF ALGORITHMS FOR IDENTIFYING SUSPECTED AND CONFIRMED HEPARIN-INDUCED THROMBOCYTOPENIA

Patel VA, Walton SM, Galanter WL, Lee TA, Schumock G, Nutescu EA, University of Illinois at Chicago, Chicago, IL, USA

PSY6 N18 pgA292 MAJOR EARLY COMPLICATIONS FOLLOWING BARIATRIC SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS

Freeman NL¹, Stoll CR¹, Carlsson NP¹, Calhoun AJ¹, Eagon JC², Colditz GA¹, Chang S¹, Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, St. Louis, MO, USA, ²Division of General Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, St. Louis, MO, USA

PSY7 O1 pgA292 ESTIMATING QUALITY OF LIFE OF PATIENTS WITH LIPODYSTROPHY

Dhankhar P¹, Isupov T¹, Araujo-Vilar D², Brown R³, Garg A⁴, Jae DH⁵, Rangel Miller V⁵, Oral E⁶, Stratton A⁷, AstraZeneca, Fort Washington, PA, USA, ²University of Santiago de Compostela, Santiago de Compostela, Spain, ³National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA, ⁴University of Texas Southwestern Medical Center, Dallas, TX, USA, ⁵Patient Crossroads, La Jolla, CA, USA, ⁶University of Michigan, Ann Arbor, MI, USA, ⁷Lipodystrophy United, Los Lunas, NM, USA

PSY8 O2 pgA292 COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH ANKYLOSING SPONDYLITIS (AS) RECEIVING ADALIMUMAB OR ETANERCEPT MONOTHERAPY IN THE UNITED STATES (US)

Narayanan S¹, Lu Y², Hutchings R², Graham CM³, Baynton E², Ipsos Healthcare, Columbia, MD, USA, ²Ipsos Healthcare, London, UK, ³Ipsos Healthcare, Boston, MA, USA

PSY9 O3 pgA293 APROTININ FREE HEMOSTATIC SEALANT TO REDUCE BLOOD LOSS IN SURGICAL PATIENTS: A SYSTEMATIC REVIEW

Luque A¹, Junqueira Junior SM², Cabra HA³, Andrade PC², Oliveira FM¹, Johnson & Johnson Medical Brazil, São Paulo, Brazil, ²Johnson & Johnson Medical Brazil, Sao Paulo, Brazil, ³Johnson & Johnson Medical, Mexico, D.F., Mexico

PSY10 O4 pgA293 COMPARATIVE EFFECTIVENESS AND SAFETY OF ARGATROBAN AND BIVALIRUDIN IN PATIENTS WITH SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA

Patel VA¹, Galanter WL¹, Lee TA¹, Schumock G¹, Nutescu EA¹, Hohmann SF², Walton SM¹, University of Illinois at Chicago, Chicago, IL, USA, ²University HealthSystem Consortium, Chicago, IL, USA

PSY11 O5 pgA293 THE ACTUAL CLINICAL USE OF ANTIFUNGAL DRUGS IN PATIENTS WHO RECEIVED HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JAPAN: A RETROSPECTIVE DATABASE STUDY

Kawabata I¹, Li Y¹, Yamamoto Y², Yamazaki T², Fujimoto Y¹, Pfizer Japan Inc, Tokyo, Japan, ²MinaCare co.ltd, Tokyo, Japan

PSY12 O6 pgA293 ROLE OF BEHAVIORAL CONFOUNDING IN THE ASSOCIATION BETWEEN MARIJUANA USE AND BMI IN US ADULTS

Thompson C¹, Hay JW², University of Southern California, Santa Monica, CA, USA, ²University of Southern California, Los Angeles, CA, USA

PSY13 O7 pgA293 SECOND PROSPECTIVE, PHARMACOEPIDEMOLOGIC DATABASE ANALYSIS OF PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE USAGE FROM A REPRESENTATIVE US SAMPLE OF OLDER PATIENTS

Peterson CA, Steelman X, Varghese ST, VIVUS, Inc, Mountain View, CA, USA

PSY14 O8 pgA294 EVALUATING TRENDS IN CHRONIC PAIN PREVALENCE IN THE UNITED STATES VETERANS HEALTH ADMINISTRATION POPULATION

Li L¹, Shrestha S¹, Baser O², Wang L¹, STATinMED Research, Plano, TX, USA, ²STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA

PSY15 O9 pgA294 USE OF HYDROCODONE/ACETAMINOPHEN: PREVALENCE AND ESTIMATING EMERGENCY DEPARTMENT VISITS

Hatfield MD, Fleming ML, University of Houston, Houston, TX, USA

PSY16 P1 pgA294 MORTALITY RISK IN PATIENTS WITH PSORIASIS

Feldman SR¹, Princic N², Zhao Y³, Barghout V⁴, Willson T⁵, Song X², Guana A⁶, Herrera V⁶, Wake Forest University School of Medicine, Winston-Salem, NC, USA, ²Truven Health Analytics, Cambridge, MA, USA, ³Novartis Pharmaceuticals, East Hanover, NJ, USA, ⁴VEB Healthcare LLC., Morristown, NJ, USA, ⁵Truven Health Analytics, Salt Lake City, UT, USA, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

SYSTEMIC DISORDERS/CONDITIONS - Cost Studies

PSY17 P2 pgA294 BUDGET IMPACT ANALYSIS OF FACTOR REPLACEMENT THERAPY WITH TUROCTOCOG ALFA IN THE TREATMENT OF HEMOPHILIA A

McQuilling CA¹, Wang Y¹, Wisniewski T², Cooper D², Iyer NN², Health Economic Consultant, New York, NY, USA, ²Novo Nordisk Inc., Plainsboro, NJ, USA

PSY18 P3 pgA294 MANAGED CARE ORGANIZATION BUDGET IMPACT OF ADDING RECOMBINANT FACTOR VIII FC FUSION

PROTEIN (RFVIIIIC) TO THE FORMULARY FOR THE TREATMENT OF HEMOPHILIA A

Buckley BC¹, Livingston TP¹, Eldar-Lissai A², Hall EC¹,¹Biogen Idec, Weston, MA, USA, ²Biogen Idec, Cambridge, MA, USA

- PSY19 P4** *pgA294* **ECONOMIC IMPLICATIONS OF INCREASING USAGE OF CALCIUM-FREE BALANCED CRYSTALLOID SOLUTIONS (BAL) VERSUS 0.9% SALINE FOR INTRAVENOUS (IV) FLUID THERAPY IN PATIENTS WITH SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) IN US HOSPITALS**
Makhija D¹, Munson S², Khangulov VS², Peyerl FW², Paluszkiwicz SM², Laplante S¹, Liu FX¹,¹Baxter Healthcare Corporation, Deerfield, IL, USA, ²Boston Strategic Partners, Inc., Boston, MA, USA
- PSY20 P5** *pgA295* **THE BUDGET IMPACT OF TREATING PATIENTS WITH NON-DIABETIC PERIPHERAL NEUROPATHIC PAIN (PNP) WITH CAPSAICIN 8% PATCH FOR EITHER PREGABALIN-NAIVE OR PREGABALIN-TREATED PATIENTS IN SCOTLAND**
Patel S¹, Chambers C², Garnham A²,¹Astellas UK, Chertsey, UK, ²Astellas Pharma EMEA, Chertsey, UK
- PSY21 P6** *pgA295* **COST IMPLICATION OF USING LORCASERIN IN WEIGHT MANAGEMENT PRIOR TO BARIATRIC SURGERY**
Wang Z¹, Li X², Knoth R², Fujioka K³,¹Eisai Inc., Woodcliff Lake, NJ, USA, ²Eisai, Inc., Woodcliff Lake, NJ, USA, ³Scripps Health, San Diego, CA, USA
- PSY22 P7** *pgA295* **COST ANALYSIS OF VORICONAZOLE VERSUS CASPOFUNGIN FOR PRIMARY THERAPY OF INVASIVE ASPERGILLOSIS AMONG HIGH-RISK HEMATOLOGIC CANCER PATIENTS IN CHINA**
Gao X¹, **Xue M**¹, Stephens J¹, Chen Y², Haider S³, Charbonneau C⁴,¹Pharmerit International, Bethesda, MD, USA, ²Pfizer Investment Co. Ltd., Beijing, China, ³Pfizer Inc, Groton, CT, USA, ⁴Pfizer Inc, Paris, France
- PSY23 P8** *pgA295* **AN ECONOMIC ANALYSIS OF POSTOPERATIVE PAIN MANAGEMENT WITH THE FENTANYL IONTOPHORETIC TRANSDERMAL SYSTEM**
Abraham J¹, Ogden K², Wang Y³, Jones J³,¹The Medicines Company, Waltham, MA, USA, ²ICON, San Francisco, CA, USA, ³The Medicines Company, Parsippany, NJ, USA
- PSY24 P9** *pgA295* **COMPARING THE ECONOMIC BURDEN OF VARIOUS DISEASES FROM A PAYER'S PERSPECTIVE IN CHINA**
Wang BC¹, Chen Y², Furnback W¹, Yang R³, Xie L²,¹Elysia Group, LLC, New York, NY, USA, ²Pfizer Investment Co. Ltd., Beijing, China, ³Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin, China
- PSY25 Q1** *pgA296* **TIMING OF FIRST-TIME USE OF BIOLOGICS AND HEALTHCARE COSTS AND UTILIZATION IN PSORIASIS**
Feldman SR¹, Herrera V², Zhao Y³, **Shi L**⁴,¹Wake Forest University School of Medicine, Winston-Salem, NC, USA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ³Novartis Pharmaceuticals, East Hanover, NJ, USA, ⁴Tulane University, New Orleans, LA, USA
- PSY26 Q2** *pgA296* **COST-MINIMIZATION ANALYSIS OF INFLIXIMAB VERSUS ADALIMUMAB IN THE TREATMENT OF CROHN'S DISEASE AND ULCERATIVE COLITIS**
De Paula E, Blumer Vd, Trevizam YC, Asano EW, Medinsight - Decisions in Healthcare, NA, Brazil
- PSY27 Q3** *pgA296* **ADHERENCE TO IRON CHELATION THERAPY AND ASSOCIATED HEALTHCARE RESOURCE UTILIZATION AND COSTS IN MEDICAID PATIENTS WITH THALASSEMIA**
Vekeman F¹, Sasane M², Cheng WY³, Agnihotram RV¹, Fortier J⁴, Duh MS³, Paley C², Adams-Graves P⁵,¹Groupe d'analyse, Montreal, QC, Canada, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ³Analysis Group, Boston, MA, USA, ⁴Groupe d'analyse, Ltée, Montreal, QC, Canada, ⁵University of Tennessee, Memphis, TN, USA
- PSY28 Q4** *pgA296* **PREVALENCE AND ECONOMIC BURDEN OF PRESCRIPTION OPIOID MISUSE AND ABUSE SYSTEMATIC REVIEW**
Oderda G¹, Lake J¹, Rudell K², Roland CL³, Masters E⁴,¹University of Utah, Salt Lake City, UT, USA, ²Pfizer Inc, Tadsworth, UK, ³Pfizer Inc, Durham, NC, USA, ⁴Pfizer, Inc., New York, NY, USA
- PSY29 Q5** *pgA296* **DEMOGRAPHIC DISTRIBUTION AND HEALTH CARE BURDEN OF PATIENTS DIAGNOSED WITH ANKYLOSING SPONDYLITIS IN THE U.S. MEDICARE POPULATION**
Mao X¹, Li L², Shrestha S², Baser O³, Yuze H⁴, **Wang L**²,¹University of Texas at Dallas and STATinMED Research, Plano, TX, USA, ²STATinMED Research, Plano, TX, USA, ³STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA, ⁴City University of New York & STATinMED Research, New York, NY, USA
- PSY30 Q6** *pgA296* **DIRECT HEALTHCARE COSTS OF OPIOID ABUSE IN PATIENTS PRESCRIBED IMMEDIATE RELEASE HYDROCODONE IN THE UNITED STATES**
Michna E¹, Chitnis A², Paramore C², **Holly P**³, Bell JA³, BenJoseph R³,¹Brigham and Women's Hospital, Chestnut Hill, MA, USA, ²Evidera, Lexington, MA, USA, ³Purdue Pharma L.P., Stamford, CT, USA
- PSY31 Q7** *pgA297* **COST PER ADDITIONAL RESPONDER ASSOCIATED WITH BIOLOGIC USE IN PSORIASIS**
Foster S, Zhu B, **Al Sawah S**, Eli Lilly and Company, Indianapolis, IN, USA
- PSY32 Q8** *pgA297* **EFFECT OF WEIGHT LOSS (WL) ON CONCOMITANT MEDICATION COSTS IN OBESE/OVERWEIGHT INDIVIDUALS WITH METABOLIC SYNDROME (METS) RECEIVING PHENTERMINE/TOPIRAMATE EXTENDED-RELEASE (PHEN/TPM ER)**

Kahan S¹, Karnawat S²,¹George Washington University School of Public Health and Health Services, Washington, DC, USA, ²VIVUS, Inc, Mountain View, CA, USA

PSY33 Q9 pgA297 **PHARMACOTHERAPEUTIC AND ECONOMIC INDICATORS OF THE USE OF IMMUNOBIOLOGICALS DRUGS: ANALYSIS OF A RHEUMATIC PATIENT COHORT**

Reis HP¹, Magalhaes Dd², Albuquerque IM², Vieira JB², Sartori DP², Candido D³, Alcantara AC², Ribeiro VD², Roldan Ad², Filho NG², Rodrigues EX²,¹UFC, Fortaleza, Brazil, ²UNIMED Fortaleza, Fortaleza, Brazil, ³Universidade Federal do Ceará, Fortaleza, Brazil

PSY34 R1 pgA297 **PROJECTING BENEFITS FROM WEIGHT LOSS IN OBESE POPULATIONS: A MICROSIMULATION APPROACH**

Chen F¹, Iacobucci W², Su W¹, Dall T¹,¹IHS Inc., Washington, DC, USA, ²IHS Life Sciences, Washington, DC, USA

PSY36 R2 pgA297 **DEMONSTRATING THE COST EFFECTIVENESS OF MOVANTIK FOR THE TREATMENT OF OPIOID INDUCED CONSTIPATION IN PATIENTS WITH INADEQUATE RESPONSE TO LAXATIVES; A UK PERSPECTIVE**

Lawson R¹, Vioix H², Mudunkotuwe S², King F³, Goh J⁴, Marsh K⁵,¹AstraZeneca, Cheshire, UK, ²AstraZeneca, Luton, UK, ³AstraZeneca, Gaithersburg, MD, USA, ⁴Evidera, Bethesda, MD, USA, ⁵Evidera, London, UK

PSY37 R3 pgA298 **COST-EFFECTIVENESS ANALYSIS OF EX-VIVO EXPANDED AUTOLOGOUS CORNEAL EPITHELIAL CELLS CONTAINING STEM CELLS TO REPAIR THE DAMAGED OCULAR SURFACE IN PATIENTS WITH MODERATE TO SEVERE LIMBAL STEM CELL DEFICIENCY DUE TO OCULAR BURNS IN THE UK**

Fordham R¹, Ciminata G¹, Madoni A², **Magni T**², Ardigò D², Pelosi D², Withe M², Sarnelli V³, Deltetto I³, Domini B³,¹University of East Anglia, Norwich, UK, ²Chiesi Farmaceutici Spa, Parma, Italy, ³Ernst & Young, Milano, Italy

PSY38 R4 pgA298 **COST-EFFECTIVENESS OF HOME-BASED FATIGUE SELF-MANAGEMENT INTERVENTION: A RANDOMIZED CONTROLLED TRIAL**

Meng H¹, Friedberg F²,¹University of South Florida, Tampa, FL, USA, ²Stony Brook University, Stony Brook, NY, USA

PSY39 R5 pgA298 **COST-EFFECTIVENESS OF RITUXIMAB VERSUS CALCINEURIN INHIBITORS FOR REFRACTORY MYASTHENIA GRAVIS**

Georgieva M¹, Wheeler S¹, Howard Jr. JF²,¹Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PSY40 R6 pgA298 **COST MINIMIZATION ANALYSIS OF EQUIPOTENT OPIOID ANALGESICS: NATIONWIDE ANALYSIS OF MEDICARE PART D STAND-ALONE PRESCRIPTION DRUG PLANS**

Li H, Patel R, University of the Pacific, Stockton, CA, USA

PSY41 R7 pgA298 **FORECASTING THE UNITED STATES LIFETIME COST AND OUTCOMES OF IVACAFTOR IN PATIENTS WITH CYSTIC FIBROSIS**

Dilokthornsakul P, Campbell JD, University of Colorado Anschutz Medical Campus, Denver, CO, USA

PSY42 R8 pgA298 **COST-UTILITY ANALYSIS OF PAIN MEDICATIONS USED TO TREAT ADULT PATIENTS WITH CHRONIC BACK PAIN IN THE UNITED STATES**

Shah D, Anupindi VR, Vaidya V, University of Toledo, Toledo, OH, USA

PSY43 R9 pgA299 **KIDNEY INVOLVEMENT IN TUBEROUS SCLEROSIS COMPLEX: THE IMPACT ON HEALTH CARE RESOURCE USE AND COSTS IN THE NETHERLANDS**

Vekeman F¹, Magestro M², **Karner P**³, Duh MS³, Nichols T³, Zonnenberg BA⁴,¹Groupe d'analyse, Montreal, QC, Canada, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ³Analysis Group, Boston, MA, USA, ⁴University Medical Center Utrecht, Utrecht, The Netherlands

SYSTEMIC DISORDERS/CONDITIONS - Patient-Reported Outcomes & Patient Preference Studies

PSY44 S1 pgA299 **CHARACTERISTICS OF COMBINATION PHARMACOTHERAPY IN PATIENTS WITH DIABETIC PAINFUL NEUROPATHY (DPN)**

Kuo K, Brixner D, Lipman A, Hung M, Oderda G, University of Utah, Salt Lake City, UT, USA

PSY45 S2 pgA299 **INITIAL IMPACT OF TELEPHARMACY ON SPECIALTY MEDICATION ADHERENCE**

Fensterheim LE¹, Gunn JG¹, Pokuta KL², Straszewski A², Marks A¹,¹Catamaran, Chicago, IL, USA, ²Catamaran, Schaumburg, IL, USA

PSY46 S3 pgA299 **UNMET NEEDS AND TREATMENT PATTERNS IN LUPUS: RESULTS FROM AN ONLINE COMMUNITY**

Wang VC, **Hanger M**, Vaughan T, Woyczynski M, Wicks P, PatientsLikeMe, Cambridge, MA, USA

PSY47 S4 pgA299 **ESTIMATING UTILITY VALUES FOR POLYCYTHEMIA VERA USING PATIENT-REPORTED OUTCOMES FROM THE RESPONSE TRIAL AND EXISTING MAPPING ALGORITHMS**

Thompson M¹, Pepper AN¹, Côté I², Oliver N³,¹Cornerstone Research Group, Burlington, ON, Canada, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ³Novartis Pharmaceuticals UK Limited, Frimley/Camberley, Surrey, UK

PSY48 S5 pgA300 **THE IMPACT OF INCREASING SEVERITY OF HEREDITARY HAEMOCHROMATOSIS ON HEALTH STATE UTILITY VALUES**

de Graaff BL, Neil A, Sanderson K, Yee KC, Palmer A, University of Tasmania, Hobart, Australia

- PSY49 S6** *pgA300* **IMPROVED HEALTH STATUS OF HAEMOPHILIA B PATIENTS TREATED WITH NONACOG BETA PEGOL, A NEW GLYCOPEGYLATED RECOMBINANT FIX PRODUCT WITH PROLONGED HALF-LIFE**
Chowdary P¹, Kearney S², Yee DL³, Meunier J⁴, Slothuus U⁵, **Hoxer CS**⁵,¹Royal Free Hospital, London, UK, ²Children's Hospital and Clinics of Minnesota, Minneapolis, MN, USA, ³Texas Children's Hemophilia & Thrombosis Center, Houston, TX, USA, ⁴Mapi, Lyon, France, ⁵Novo Nordisk A/S, Søborg, Denmark
- PSY50 S7** *pgA300* **USE OF INFLIXIMAB WITHIN A PATIENT SUPPORT PROGRAM: POSITIVE PERCEPTION OF IV INFUSIONS FROM PATIENTS' PERSPECTIVE**
Dyrda P¹, O'Reilly R², Williamson M¹, Dajnowiec D¹, Jones J³, Borgaonkar M⁴, Siffledeen J⁵, Anger D⁶, Thompson M⁶,¹Janssen Inc., Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Dalhousie University, Halifax, NS, Canada, ⁴Memorial University, St. John's, NF, Canada, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Cornerstone Research Group, Burlington, ON, Canada
- PSY51 S8** *pgA300* **POTENTIAL PATIENT-REPORTED PREDICTORS OF OPENNESS TO AND PREFERENCE FOR BIOLOGIC THERAPY AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE**
Goren A¹, Teeple A², **Ingham M**²,¹Kantar Health, New York, NY, USA, ²Janssen Scientific Affairs, LLC, Horsham, PA, USA
- PSY52 S9** *pgA300* **IBRUTINIB FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): EVALUATING THE CORRELATION BETWEEN PATIENT-REPORTED OUTCOMES AND DURABILITY OF RESPONSE IN A PHASE 2 STUDY**
Rule S¹, Goy A², Martin P³, Ramchandren R⁴, Alexeeva J⁵, Popat R⁶, Avivi I⁷, Advani R⁸, Le Gouill S⁹, Horowitz N¹⁰, Yuan Z¹¹, Kranenburg B¹², Zhuang SH¹¹, Deraedt W¹³, Rizo A¹¹, **Wildgust M**¹¹, Wang M¹⁴,¹Derriford Hospital, Plymouth, UK, ²John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA, ³Weill Cornell Medical College, New York, NY, USA, ⁴Wayne State University Hudson-Webber Cancer Research Center, Detroit, MI, USA, ⁵Federal Medical Research Center, St. Petersburg, Russia, ⁶University College London Hospitals NHS Foundation Trust, London, UK, ⁷Tel Aviv Medical Center, Tel Aviv, Israel, ⁸Stanford Cancer Institute, Palo Alto, CA, USA, ⁹Service d'hématologie clinique Université de Nantes, Nantes, France, ¹⁰Rambam Health Care Campus, Haifa, Israel, ¹¹Janssen Research & Development, LLC, Raritan, NJ, USA, ¹²Janssen Biologics B.V., Leiden, The Netherlands, ¹³Janssen Research & Development, LLC, Beerse, Belgium, ¹⁴The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- PSY53 T1** *pgA301* **CORRELATION BETWEEN PAIN CATASTROPHIZING SCALE AND DISEASE CHARACTERISTICS IN CHRONIC LOW BACK PAIN PATIENTS**
Lavudiya S¹, Bansal D², Ghai B³, Gudala K²,¹National Institute of Pharmaceutical Educational and Research, Mohali, India, ²National Institute of Pharmaceutical Education and Research, Mohali, India, ³Postgraduate Institute of Medical Education and Research, Chandigarh, India
- PSY54 T2** *pgA301* **A REVIEW OF PATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS WITH CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)**
Ogunsanya M¹, Kalb S², Chen S²,¹The University of Texas at Austin, Austin, TX, USA, ²Biogen Idec, Cambridge, MA, USA
- PSY55 T3** *pgA301* **SHARED DECISION MAKING AMONG PATIENTS WITH AUTOIMMUNE CONDITIONS INITIATING BIOLOGIC THERAPY: INITIAL FINDINGS**
Lofland J¹, Johnson PT², Watkins A², White JC²,¹Janssen Scientific Affairs, LLC, Horsham, PA, USA, ²Optum, Eden Prairie, MN, USA
- PSY56 T4** *pgA301* **SYSTEMATIC REVIEW OF THE PATTERNS OF USE, CHARACTERISTICS, AND QUALITY OF PATIENT REPORTED OUTCOME MEASURES IN CELIAC DISEASE**
Canestaro WJ, Edwards TC, Patrick DL,¹University of Washington, Seattle, WA, USA
- PSY57 T5** *pgA301* **PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS WITH TYPE 1 MYOTONIC DYSTROPHY TYPE 1 – A SYSTEMATIC LITERATURE REVIEW**
Ogunsanya M¹, Kalb S², Yeh W²,¹The University of Texas at Austin, Austin, TX, USA, ²Biogen Idec, Cambridge, MA, USA
- PSY58 T6** *pgA301* **PAIN FUNCTIONAL IMPAIRMENT AND QUALITY OF LIFE (P-FIQ): AN ASSESSMENT OF RELIABILITY OF FIVE PATIENT REPORTED OUTCOME (PRO) INSTRUMENTS IN ADULT PEOPLE WITH HEMOPHILIA (PWH)**
Kempton CL¹, Wang M², Recht M³, Neff A⁴, Shapiro AD⁵, Buckner T⁶, Kulkarni R⁷, Nugent D⁸, Batt K⁹, Wisniewski T¹⁰, **Cooper DL**¹⁰,¹Emory University School of Medicine, Atlanta, GA, USA, ²Children's Hospital Colorado, Aurora, CO, USA, ³Oregon Hemophilia Treatment Center, Portland, OR, USA, ⁴Vanderbilt University Medical Center, Nashville, TN, USA, ⁵Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA, ⁶University of Colorado School of Medicine, Aurora, CO, USA, ⁷Michigan State University, East Lansing, MI, USA, ⁸Children's Hospital of Orange County and UC Irvine Department of Pediatrics, Orange, CA, USA, ⁹Wake Forest School of Medicine, Winston-Salem, NC, USA, ¹⁰Novo Nordisk Inc., Plainsboro, NJ, USA
- PSY59 T7** *pgA302* **MEASUREMENT PROPERTIES OF WEB BASED LUPUSPRO, A DISEASE TARGETED OTCOME TOOL, AMONG ITALIAN PATIENTS WITH LUPUS**
Jolly M¹, Mazzoni D², Cicognani E²,¹Rush University Medical Center, Chicago, IL, USA, ²University of Bologna, Bologna, Italy
- PSY60 T8** *pgA302* **IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE FOR SICKLE CELL DISEASE PATIENTS**

TREATED WITH CHEMOTHERAPY-FREE ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION: A PILOT STUDY

Jalunhwala YJ, Saraf SL, Rondelli D, Law EH, Pickard AS, University of Illinois at Chicago, Chicago, IL, USA


SYSTEMIC DISORDERS/CONDITIONS - Health Care Use & Policy Studies

- PSY61 T9** pgA302 **CHARACTERISTICS OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) CURRENTLY EXPERIENCING FLARES IN CLINICAL PRACTICE SETTINGS IN EUROPE (EU)**
Narayanan S¹, Hutchings R², Lu Y^{2,1}Ipsos Healthcare, columbia, MD, USA, ²Ipsos Healthcare, London, UK
- PSY62 U1** pgA302 **TRENDS IN APPROVALS OF NEW DRUGS WITH ORPHAN DESIGNATION IN THE US (1983-2014)**
Alhawwashi ST¹, Alshahrani AM¹, Alsaahli SM¹, Alasmari MS¹, Seoane-Vazquez E², Rodriguez-Monguio R³, Szeinbach SL^{4,1}, Massachusetts college of pharmacy and health science, Boston, MA, USA, ²MCPHS University, Boston, MA, USA, ³University of Massachusetts, Amherst, Amherst, MA, USA, ⁴The Ohio State University, Columbus, OH, USA
- PSY63 U2** pgA302 **DETERMINING PATTERNS OF OPIOID MISUSE AND MISPREScribing IN SOUTH CAROLINA**
Qureshi Z¹, Ball S², Horner R¹, Kreiner P³, Lopez-Defede A¹, Probst J⁴, Bennett C⁵, ¹University of South Carolina, Columbia, SC, USA, ²South Carolina College of Pharmacy, Charleston, SC, USA, ³Brandeis University, Waltham, MA, USA, ⁴University of South Carolina, COLUMBIA, SC, USA, ⁵University of South Carolina College of Pharmacy, Columbia, SC, USA
- PSY64 U3** pgA303 **TREATMENT PATTERNS AMONG CHRONIC USERS OF IMMEDIATE-RELEASE OXYCODONE INITIATING TREATMENT WITH EXTENDED-RELEASE OPIOIDS**
Pergolizzi JV¹, Kirson NY², Bell J³, Jones C⁴, Mantovanelli F², Cummings AG², Birnbaum HG⁵, Ben-Joseph R^{3,1}, Naples Anesthesia and Pain Associates, INC., Bonita Springs, FL, USA, ²Analysis Group, Inc., Boston, MA, USA, ³Purdue Pharma L.P., Stamford, CT, USA, ⁴Analysis Group, In, Boston, MA, USA, ⁵Analysis Group, Boston, MA, USA
- PSY65 U4** pgA303 **CROSS-STATE COMPARISON OF MEDICAID ANTI-OBESITY MEDICATION COVERAGE: 1999-2013**
Xia Y, Kelton CM, Heaton PC, Guo JJ, University of Cincinnati, Cincinnati, OH, USA
- PSY66 U5** pgA303 **HYDROCODONE: A REVIEW OF THE LITERATURE**
Hatfield MD, Fleming ML, University of Houston, Houston, TX, USA
- PSY67 U6** pgA303 **ESTIMATION OF MEDICAL EXPENDITURE ASSOCIATED WITH OPIOIDS USAGE IN CHRONIC NON-CANCER PAIN: A CROSS-SECTIONAL STUDY BASED ON MEDICAL EXPENDITURE SURVEY AND PANEL DATA**
Zhang Y, Dana Farber Cancer Institution, boston, MA, USA
- PSY68 U7** pgA303 **DOSING PATTERN ANALYSIS FOR BIOLOGICS IN THE TREATMENT OF PSORIASIS IN CANADA: INDICATION-SPECIFIC INFORMATION RETRIEVED FROM ADMINISTRATIVE CLAIMS DATABASE**
Gregory V¹, Liu N², Robertson C², Gerega S³, Barbeau M¹, Budry L^{4,1}, Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, ²IMS Health, Mississauga, ON, Canada, ³IMS Health, Kirkland, QC, Canada, ⁴Université de Montréal, Montreal, QC, Canada
- PSY69 V1** pgA304 **EFFECT OF FLORIDA'S PRESCRIPTION MONITORING PROGRAM AND PILL-MILL LAWS ON OPIOID PRESCRIBING AND UTILIZATION**
Daubresse M¹, Rutkow L¹, Chang H¹, Stuart E¹, Webster D¹, Alexander GC^{2,1}, Johns Hopkins School of Public Health, Baltimore, MD, USA, ²Johns Hopkins School of Public Health, Center for Drug Safety and Effectiveness, Baltimore, MD, USA
- PSY70 V2** pgA304 **THE CHANGING COSTS OF CARING FOR HEMOPHILIA PATIENTS IN THE U.S.: INSURERS' AND PATIENTS' PERSPECTIVES**
Eldar-Lissai A, Hou Q, Krishnan S, Biogen Idec, Cambridge, MA, USA
- PSY71 V3** pgA304 **INCREASED LENGTH OF STAY FOR OBESE PATIENTS BY CHRONIC DISEASE**
Hoshen MB, Leventer-Roberts M, Balicer R, Clalit Research Institute, Tel Aviv, Israel
- PSY72 V4** pgA304 **THE AVAILABILITY AND EXPENDITURE OF ORPHAN MEDICINES IN POLAND**
Sujkowska G, Jagodzinska-Kalinowska K, Matuszewicz W, Agency for Health Technology Assessment and Tariff System, Warsaw, Poland
- PSY73 V5** pgA304 **BARIATRIC SURGERY IN THE BRAZILIAN HEALTH CARE SYSTEM: RESOURCES UTILIZATION**
Junqueira Junior SM¹, Andrade PC¹, Cabra HA², Luque A¹, Oliveira FM^{3,1}, Johnson&Johnson Medical Brazil, Sao Paulo, Brazil, ²Johnson & Johnson Medical, Mexico, D.F., Mexico, ³Johnson & Johnson Medical Brazil, São Paulo, Brazil
- PSY74 V6** pgA304 **CANADIAN RETROSPECTIVE CLAIMS DATA ANALYSIS OF BIOLOGICS SWITCHING AND RETENTION PATTERNS IN PSORIASIS PATIENTS**
Millson B¹, Poulin-Costello M², Garces K^{2,1}, IMS Brogan, Kirkland, QC, Canada, ²Amgen Canada Inc., Mississauga, ON, Canada
- PSY75 V7** pgA305 **COMPARISON OF ULTRA ORPHAN AND CANCER DRUG PRICING IN THE US AND THE UK**
Kumar S¹, Aggarwal S², Topaloglu H^{2,1}, GLOBAL ACCESS Monitor, Bethesda, MD, USA, ²NOVEL Health

Strategies, Chevy Chase, MD, USA

- PSY76 W1** *pgA305* **ORPHAN DRUG DESIGNATION: A COMPARISON OF POLICIES, PROCESSES AND RESULTS FROM THE US AND THE EU**
Shields GE¹, Arranhado Neves AC¹, Bajpai SK²,¹BresMed, Sheffield, UK, ²Institute of Pharmaceutical Management, Yardley, PA, USA
- PSY77 W2** *pgA305* **TIMING OF EU5 & US ORPHAN DRUG APPROVALS AND PRMA BETWEEN 2009 AND 2013**
Mycka J¹, Dellamano R², Lobb W¹, Dalal N¹, Pereira E¹, Dellamano L², Sagaydachnaya O¹, Lue J¹,¹Medical Marketing Economics LLC (MME), Montclair, NJ, USA, ²ValueVector, Milan, Italy
- PSY78 W3** *pgA305* **DRIVERS OF HEALTHCARE RESOURCE UTILIZATION AND FACTORS ASSOCIATED WITH INCREASED RESOURCE USE IN PATIENTS WITH FIBROMYALGIA: AN EVALUATION USING ELECTRONIC MEDICAL RECORDS**
Margolis J¹, Masters ET², Cappelleri JC³, Smith DM⁴, Faulkner ST⁵, Thompson E⁴,¹Truven Health Analytics, Bala Cynwyd, PA, USA, ²Pfizer Inc., New York, NY, USA, ³Pfizer Inc., Groton, CT, USA, ⁴Truven Health Analytics, Bethesda, MD, USA, ⁵Pfizer Inc., Edwardsville, IL, USA
- PSY79 W4** *pgA305* **SUGAR-SWEETENED BEVERAGES CONSUMPTION AND PRICE SENSITIVITY AMONG BRAZILIAN ADULTS: IMPLICATIONS FOR OBESITY POLICIES**
Cardoso LB, UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL, PORTO ALEGRE, Brazil
- PSY80 W5** *pgA305* **WHY ASK IF YOU KNOW? ACMG'S POTENTIAL ERRORS IN MAKING NEWBORN SCREENING (NBS) RECOMMENDATIONS FROM USING SURVEYED OPINIONS FOR INCIDENCE SCORING WHEN ACTUAL DATA ARE AVAILABLE**
Algarni M, Almutairi H, Rittenhouse B, MCPHS University, Boston, MA, USA
- PSY81 W6** *pgA306* **HOW MUCH IS NICE REALLY PREPARED TO PAY FOR ORPHAN AND END-OF-LIFE DRUGS?**
Griffiths EA, Martin RL, HERON Commercialization, London, UK
- PSY82 W7** *pgA306* **HOW INFLUENTIAL ARE PATIENT AND PROFESSIONAL GROUP SUBMISSIONS ON REIMBURSEMENT DECISIONS FOR EUROPEAN MEDICINES AGENCY ORPHAN DRUGS?**
Chang R, Versoza L, Jaksa A, Ho Y, Context Matters, New York, NY, USA
- PSY83 W8** *pgA306* **TREATMENT OF OBESITY: PHARMACOTHERAPY TRENDS IN THE UNITED STATES FROM 1999 TO 2010**
Xia Y, Kelton CM, Heaton PC, Guo JJ, University of Cincinnati, Cincinnati, OH, USA
- PSY84 X1** *pgA306* **IMPLEMENTATION OF A STATEWIDE OPIATE PRESCRIBING POLICY IS NOT ASSOCIATED WITH A SIGNIFICANT DECREASE IN OPIATE PRESCRIPTIONS FROM THE EMERGENCY DEPARTMENT**
McGhee JD, Bounds RB, Papas MA, Coletti C, Christiana Care Health System, Newark, DE, USA
- PSY85 X2** *pgA306* **ASSESSING THE IMPACT OF VARYING THRESHOLD CRITERIA FOR OPIOID OVERUTILIZATION**
Durkin M¹, Moll K², Pasquale MK², Amos T¹, Null KD²,¹Janssen Scientific Affairs, LLC, Titusville, NJ, USA, ²Comprehensive Health Insights, Louisville, KY, USA

RESEARCH POSTER PRESENTATIONS FLOOR PLAN



Looking for poster presentations online?

The **ISPOR Scientific Presentations Database** is a searchable database of over 31,500 research papers presented at ISPOR meetings since 1998. The database is searchable by disease, topic, meeting, key word and author. To access the database, go to www.ispor.org and click the purple "Scientific Presentations" tab.

ISPOR



Scientific Presentations Database

